Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Sep 6;19(9):e0309965. doi: 10.1371/journal.pone.0309965

Strategies found not to be suitable for stabilizing high steroid hydroxylation activities of CYP450 BM3-based whole-cell biocatalysts

Carolin Bertelmann 1,2, Bruno Bühler 1,2,*
Editor: Dirk Tischler3
PMCID: PMC11379211  PMID: 39240904

Abstract

The implementation of biocatalytic steroid hydroxylation processes plays a crucial role in the pharmaceutical industry due to a plethora of medicative effects of hydroxylated steroid derivatives and their crucial role in drug approval processes. Cytochrome P450 monooxygenases (CYP450s) typically constitute the key enzymes catalyzing these reactions, but commonly entail drawbacks such as poor catalytic rates and the dependency on additional redox proteins for electron transfer from NAD(P)H to the active site. Recently, these bottlenecks were overcome by equipping Escherichia coli cells with highly active variants of the self-sufficient single-component CYP450 BM3 together with hydrophobic outer membrane proteins facilitating cellular steroid uptake. The combination of the BM3 variant KSA14m and the outer membrane pore AlkL enabled exceptionally high testosterone hydroxylation rates of up to 45 U gCDW-1 for resting (i.e., living but non-growing) cells. However, a rapid loss of specific activity heavily compromised final product titers and overall space-time yields. In this study, several stabilization strategies were evaluated on enzyme-, cell-, and reaction level. However, neither changes in biocatalyst configuration nor variation of cultivation media, expression systems, or inducer concentrations led to considerable improvement. This qualified the so-far used genetic construct pETM11-ksa14m-alkL, M9 medium, and the resting-cell state as the best options enabling comparatively efficient activity along with fast growth prior to biotransformation. In summary, we report several approaches not enabling a stabilization of the high testosterone hydroxylation rates, providing vital guidance for researchers tackling similar CYP450 stability issues. A comparison with more stable natively steroid-hydroxylating CYP106A2 and CYP154C5 in equivalent setups further highlighted the high potential of the investigated CYP450 BM3-based whole-cell biocatalysts. The immense and continuously developing repertoire of enzyme engineering strategies provides promising options to stabilize the highly active biocatalysts.

Introduction

Steroid hydroxylations hold significant relevance for the pharmaceutical industry due to the vast scope of hydroxylated steroid derivatives displaying specific pharmacological activities, e.g., anti-inflammatory, contraceptive, or immunosuppressive effects, but, being formed in the liver, also adverse effects making them relevant for drug approval processes [1, 2]. Desired reactions typically are accomplished using cytochrome P450 monooxygenases (CYP450s) which offer an enormous biocatalytic versatility regarding substrate, regio-, and stereoselectivity [1, 3]. Despite their impressive synthetic potential, native steroid-hydroxylating CYP450s suffer from drawbacks that often hamper their biotechnological use. Commonly observed limitations include poor catalytic activity, instability in isolated form, as well as insufficient selectivity [46]. They require an external electron donor, more specifically NAD(P)H, which supplies the electrons necessary for reductive O2 activation [7, 8]. The majority of CYP450s furthermore depends on specific redox proteins enabling the electron transfer to the heme iron in the active site [4, 5, 7, 9]. Respective subunits need to be expressed in a stable and active form and in the optimal ratio [10, 11], with a crucial influence on biotransformation efficiency [12, 13]. Biocatalytic steroid hydroxylation therefore is expected to benefit from self-sufficient systems such as CYP450 BM3 from Bacillus megaterium ATCC14581, in which both the heme-containing monooxygenase and FAD/FMN-containing reductase functionalities are combined in a single polypeptide [14, 15].

In our previous research, we applied highly active BM3 variants [16] in living Escherichia coli cells for testosterone hydroxylation [17]. Typically, whole-cell biocatalysts represent the preferred format for CYP450 catalysis, since they allow for enzyme resynthesis and stabilization, cofactor recycling, and reactive oxygen species (ROS) degradation [12, 18, 19]. In order to relieve limiting cellular uptake of the substrate testosterone, the hydrophobic outer membrane pore AlkL from Pseudomonas putida GPo1 was introduced. The genes encoding different BM3 variants and AlkL were co-expressed from a bicistronic operon under control of the lacI-PT7-based regulatory system (S1A Fig) on the pETM11 vector, giving the recombinant strain E. coli BL21-Gold(DE3)_pETM11-ksa14m-alkL. Resulting whole-cell biocatalysts showed exceptionally high specific testosterone hydroxylation rates [17], which exceeded those reported for other testosterone-hydroxylating CYP450 systems by a factor of up to 264 [20, 21]. Resting (i.e., metabolically active but non-growing) E. coli cells harboring AlkL and the BM3 variant KSA14m displayed the highest specific activity (45 U gCDW-1), paving the way towards unprecedented product titers and space-time yields for steroid hydroxylation processes. However, poor operational stability of this whole-cell biocatalyst has been confirmed [22]. A systematic evaluation of kinetics and stability identified limited substrate availability due to poor testosterone solubility, product inhibition, and enzyme instability as critical factors. The latter appeared to involve enzyme inactivation rather than degradation and occurred independently from the presence of substrate and products, revealing an inherent instability of KSA14m possibly via uncoupling [22]. Engineered BM3 variants often suffer from poor coupling between product formation and NAD(P)H consumption, which typically involves ROS formation [16, 23]. Such oxidative stress can harm both protein function and cell physiology [2426] and thus is detrimental for biocatalytic reactions relying on active metabolism [27]. All in all, especially KSA14m instability constrained both process efficiency and durability and consequently constitutes an optimization target for improving testosterone hydroxylation using the reported BM3 variant KSA14m.

Numerous strategies on enzyme, cell, and reaction level have proven successful for the stabilization of oxygenase-based catalysis [27] and thus constitute targets of this study for the optimization of KSA14m-based testosterone hydroxylation in E. coli. Whole-cell biocatalyst performance relies on the cellular machinery providing energy and reduction equivalents for the synthesis of functional enzymes and the reaction itself. In this work’s context, reactions catalyzed by the BM3 variant KSA14m are linked to cellular metabolism by the redox cofactor NADPH. Since the metabolic activity necessary for energy and redox equivalent supply is closely connected to the physiological state of cells, the cultivation medium and conditions are decisive for biocatalyst performance [28]. Resting E. coli cells, as employed in our previous studies [17, 22], have displayed superior whole-cell activities for redox biocatalysis compared to growing cells [29, 30]. However, as this condition is effectuated by the lack or depletion of, e.g., nitrogen sources in the medium [31], this biocatalyst format often is associated with poor stability [30, 32]. Interestingly, specific activities of magnesium-limited resting cells have been observed as more stable than those of nitrogen-deprived cells, highlighting the type of nutrient starvation as a possible stabilizing aspect for evaluation [33]. The application of growing instead of resting cells also can improve biocatalyst stability due to efficient (re-)synthesis of recombinant enzymes such as oxygenases [18] as well as more efficient handling of biocatalysis-related burdens like oxidative stress and product inhibition [30, 34]. Furthermore, adjusting oxygenase expression to a level that can be managed by cellular metabolism has proven beneficial for whole-cell biocatalyst stabilization [27]. To meet this purpose, fine-tunings of gene expression [35, 36] and cultivation media [28] represent promising strategies. Also the use of pseudomonads as microbial hosts may promote functional CYP450 synthesis, as, in contrast to E. coli, they feature intrinsic CYP450 genes and thus more efficient heme synthesis. Lastly, engineering the substrate binding pocket of CYP450s has been reported to considerably increase coupling efficiencies [3739] and consequently may reduce oxidative stress and improve enzyme stability.

In this study, we set out to stabilize biocatalytic testosterone hydroxylation with E. coli cells harboring the BM3 variant KSA14m and AlkL as biocatalyst. Their performance was evaluated in different physiological states, cultivation media, and with various gene expression systems as well as inducer concentrations. Pseudomonas taiwanensis VLB120_Strep was investigated as alternative host. Further, KSA14m was engineered based on amino acid substitutions previously found to improve the coupling efficiency of a propane-hydroxylating BM3 variant [37]. Lastly, we compared specific activities and operational stability of E. coli BL21-Gold(DE3)_pETM11-ksa14m-alkL with those of cells carrying the natively steroid-hydroxylating oxygenases CYP106A2 and CYP154C5.

Materials and methods

Chemicals, gene synthesis, and oligonucleotides

2β- and 15β-hydroxytestosterone were obtained from Steraloids Inc. (Newport, RI, USA). All other chemicals were purchased from AppliChem (Darmstadt, Germany), Carl Roth (Karlsruhe, Germany), Chemsolute (Renningen, Germany), or Sigma-Aldrich (Steinheim, Germany) in the highest purity available. Custom synthesized genes and oligonucleotides were acquired from Eurofins (Ebersberg, Germany).

Generation of recombinant bacterial strains

Microbial strains and plasmids used in this work are listed in Table 1. E. coli DH5α was used for cloning purposes, whereas E. coli BL21-Gold(DE3) or P. taiwanensis VLB120_Strep were used for expression and biotransformation studies. Electro-competent E. coli and P. taiwanensis cells were prepared as reported earlier [40, 41]. Plasmids were introduced via electroporation (2500 V, Eppendorf Eporator®, Hamburg, Germany).

Table 1. Bacterial strains and plasmids used in this study.

Strain or plasmid Characteristics Host organisms in this study Reference
Strains
E. coli DH5α supE44 ΔlacU169(Φ80 lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 [42]
E. coli BL21-Gold(DE3) FompT hsdS(rBmB) dcm+ TetR galλ(DE3) endA Hte Agilent Technologies Santa Clara, USA
P. taiwanensis VLB120_Strep solvent-tolerant, styrene-degrading bacterium, isolated from forest soil, StrepR on megaplasmid pSty (encodes solvent-tolerance genes) [43]
Plasmids
 pETM11 pMB1 ori, lac-regulatory system (lacI, PT7), KmR, pETM11 RBS EMBL Vector collection, Heidelberg, Germany
 pCOM10 broad-host-range expression vector (pRO1600 and ColE1 ori), alk-regulatory system (alkS, PalkB), KmR, pCOM10 RBS [44]
 pCOM10_lac pCOM10 derivative, lac-regulatory system (lacI, PlacUV5) [45]
 pCOM10_tac pCOM10 derivative, lac-regulatory system (lacIq, Ptac) [46]
 pACYC_Duet1 P15A ori, lac-regulatory system (lacI, 2x PT7), CmR, pACYC RBS Merck KGaA, Darmstadt, Germany
 pETM11-ksa14m-alkL pETM11 derivative with 6xHis-tagged BM3 mutant gene ksa14m and alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3) [17]
 palk-ksa14m-alkL pCOM10 derivative with 6xHis-tagged BM3 mutant gene ksa14m and alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3); This study
P. taiwanensis VLB120_Strep
 plac-ksa14m-alkL pCOM10_lac derivative with 6xHis-tagged BM3 mutant gene ksa14m and alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3); P. taiwanensis VLB120_Strep This study
 ptac-ksa14m-alkL pCOM10_tac derivative with 6xHis-tagged BM3 mutant gene ksa14m and alkL gene from P. putida GPo1 P. taiwanensis VLB120_Strep This study
 plac-ksa14m pCOM10_lac derivative with 6xHis-tagged BM3 mutant gene ksa14m P. taiwanensis VLB120_Strep This study
 plac-ksa14m-fhuAΔ1–160 pCOM10_lac derivative with 6xHis-tagged BM3 mutant gene ksa14m and fhuAΔ1–160 gene from E. coli MG1655 P. taiwanensis VLB120_Strep This study
 plac-ksa14m-todX pCOM10_lac derivative with 6xHis-tagged BM3 mutant gene ksa14m and todX gene from P. putida F1 P. taiwanensis VLB120_Strep This study
 pETM11-ksa14m(M82A)-alkL pETM11 derivative with 6xHis-tagged BM3 mutant gene ksa14m carrying M82A mutation and alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3) This study
 pETM11-ksa14m(L188P)-alkL pETM11 derivative with 6xHis-tagged BM3 mutant gene ksa14m carrying L188P mutation and alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3) This study
 pETM11-ksa14mutations-alkL pETM11 derivative with 6xHis-tagged BM3 mutant gene ksa14m carrying further mutations (L52I, A184V, I366V, G443A, D698G) and alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3) This study
 pET154-camAB pETM11 derivative with codon-optimized 6xHis-tagged cyp154c5 gene from Nocardia farcinica IFM 10152, camA and camB genes from P. putida DSM50198 E. coli BL21-Gold(DE3) This study
 pET154-camAB-alkL pET154c5-camAB derivative with alkL gene E. coli BL21-Gold(DE3) This study
 pACYC-camAB pACYC derivative with camA and camB genes from P. putida DSM50198 E. coli BL21-Gold(DE3) This study
 ptac154 pCOM10_tac derivative with codon-optimized cyp154c5 gene from Nocardia farcinica IFM 10152 E. coli BL21-Gold(DE3) This study
 ptac154A ptac154 derivative with alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3) This study
 ptac106 pCOM10_tac derivative with codon-optimized cyp106a2 from B. megaterium ATCC 13368 E. coli BL21-Gold(DE3) This study
 ptac106A ptac106 derivative with alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3) This study
 pET154 pETM11 derivative with codon-optimized cyp154c5 gene from N. farcinica IFM 10152 E. coli BL21-Gold(DE3) This study
 pET154A pET154 derivative with alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3) This study
 pET106 pETM11 derivative with codon-optimized cyp106a2 from B. megaterium ATCC 13368 E. coli BL21-Gold(DE3) This study
 pET106A pET106 derivative with alkL gene from P. putida GPo1 E. coli BL21-Gold(DE3) This study

For detailed information about plasmid construction, see S1 Table. Required genes were either amplified from existing plasmids, genomic DNA, or ordered as gene synthesis constructs. Enzymes (Phusion High Fidelity Polymerase, Q5 High Fidelity Polymerase, restriction enzymes, T5 exonuclease, Taq DNA ligase), dNTPS, and the corresponding buffers were obtained from Thermo Scientific Molecular Biology (St. Leon-Rot, Germany) or New England Biolabs (Frankfurt/Main, Germany). Plasmid isolation and purification of DNA from agarose gels or PCR mixtures were conducted using respective kits from Macherey-Nagel (Düren, Germany) according to supplier protocols. The Gibson Master Mix was prepared according to Gibson et al. [47]. Successful cloning was confirmed by sequencing (Genewiz Germany GmbH, Leipzig, Germany).

To construct the plasmid pETM11-ksa14mutations-alkL, the gene ksa14mutations was ordered as gene synthesis construct from Eurofins. The vector pETM11-ksa14m-alkL [17] was used as backbone. Both ksa14mutations and the pETM11-ksa14m-alkL were digested with NcoI and SacI, followed by ligation with T4 DNA Ligase (Thermo Fisher) according to the manufacturer’s instructions.

Site-directed mutagenesis of ksa14m

Site-directed mutagenesis PCR was performed in order to incorporate the desired nucleotide exchanges into the ksa14m gene (for details see S2 Table). Desired plasmids were pETM11-ksa14m(M82A)-alkL and pETM11-ksa14m(L188P)-alkL, respectively. The forward primer contained the target mutation and included at least 10 complementary nucleotides on the 3’ side of the mutation. The reverse primer was designed so that the 5’ ends of the two primers anneal back-to-back. The vector pETM11-ksa14m-alkL [17] served as DNA template. PCR resulted in the formation of non-nicked, linearized plasmids. DNA was purified from the reaction mixtures using the NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel) and then digested with DpnI to remove methylated template DNA. The resulting reaction mixture was introduced into E. coli DH5α and desired mutations were verified via sequencing (Genewiz Germany GmbH).

Cultivation of microbial strains

Cell cultivations were carried out in baffled Erlenmeyer shake flasks with a liquid volume of maximally 20% of the total volume in a Multitron shaker (Infors, Bottmingen, Switzerland). Microorganisms were either grown in lysogeny broth medium (LB) [40] or in minimal media (M9 [40], M9* [35], or Riesenberg (RB) [48]) with a pH of 7.2 (see S3 Table for media compositions and preparation). Minimal media contained 0.5% (w/v) D-glucose as sole carbon and energy source. Kanamycin (50 μg mL-1) or chloramphenicol (34 μg mL-1) were added when appropriate.

E. coli cells from a frozen glycerol stock were cultivated in LB medium at 37°C and 200 rpm for 6-8 h. This preculture was used to inoculate an M9, M9*, or RB preculture (1% v/v). Incubation was continued at 30°C and 200 rpm for 14–16 h. From this preculture, M9, M9*, or RB main cultures were inoculated to an optical density of 0.2 at 450 nm (OD450). Heterologous gene expression was induced in the early exponential phase (OD450 ~0.6) by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) for PT7/PlacUV5/Ptac-based vectors or dicyclopropyl ketone (DCPK) for the PalkB-based regulatory system (concentrations are indicated in the figure legends and corresponding descriptions). Simultaneously, 0.5 mM of the heme precursor 5-aminolevulinic acid were added for enhanced heme synthesis. Incubation was continued either at 30°C for 5 h or at 20°C for 16 h. Cells were then harvested by centrifugation (5,000 g, 5 min) at 4 or 20°C to be employed in biotransformation experiments with resting and growing cells, respectively.

Cultivation of P. taiwanensis was similar to that of E. coli with the following adjustments: LB precultures were incubated at 30°C and 200 rpm for 20 h. M9 pre- and main cultures were treated as described for E. coli except for the addition of 5-aminolevulinic acid. Streptomycin (100 μg mL-1) was added to LB pre-cultures, but not in minimal media. Cells were harvested 5 h after induction by centrifugation (5,000 g, 5 min) at 20°C for resting-cell biotransformations [45].

Biotransformation with resting E. coli cells

After cultivation, induction, and harvesting as described above, resulting cell pellets were washed once and then resuspended in different buffers to a cell concentration of 1 gCDW L-1 (unless stated otherwise). Buffers included 100 mM potassium phosphate buffer (pH 7.4, KPi buffer) supplemented with 1% (w/v) glucose for a resting-cell state based on nitrogen limitation and M9 medium (pH 7.4) lacking magnesium and containing 1% (w/v) glucose for a resting-cell state based on magnesium limitation. Resting-cell biotransformations were performed at 30°C and 250 rpm at a 1 mL-scale in screw-capped glass tubes (12 mL) and were initiated after 15 min of equilibration by addition of 10 μL of a 100 mM steroid stock solution in DMSO, resulting in final concentrations of 1 mM steroid and 1% (v/v) DMSO. Testosterone was used as substrate for KSA14m and CYP106A2, whereas progesterone was added for CYP154C5-catalyzed steroid hydroxylation. One hundred μL sample were taken after different time intervals and mixed with 12.5 μL HCl (1 M) to stop the reaction. Pure acetonitrile was added (50% v/v) to dissolve precipitated steroids, followed by mixing on a ThermoMixer C (Eppendorf, Hamburg, Germany at 2000 rpm, 5 min, 4°C) and centrifugation (17,000 g, 5 min, 4°C) for biomass removal. The resulting supernatant was stored at -20°C until further analysis. All assays were conducted in biological duplicates for each condition. Specific activities are given in U gCDW-1, with 1 U defined as the activity forming 1 μmol of product per min, and were retrieved via quantification of accumulated product divided by the biomass concentration applied.

Biotransformation with growing E. coli cells

Cells were harvested before and 5 h after induction. Resulting pellets were washed once and resuspended in pre-warmed M9 medium (S3 Table) including IPTG, 5-aminolevulinic acid, and 1% (w/v) glucose. Ten mL of sample were filled into screw-capped, baffled flasks (100 mL) and equilibrated at 30°C and 250 rpm for 15 min. Biotransformations were started by adding 100 μL of a 100 mM testosterone stock solution in DMSO, leading to final concentrations of 1 mM testosterone and 1% (v/v) DMSO. Reaction termination and sampling were conducted as described above for resting-cell biotransformations.

Biotransformation with resting P. taiwanensis cells

Fresh cells were harvested from M9 cultures 5 h after induction and applied in nitrogen-limited resting-cell activity assays as described above for E. coli. Cell harvesting and resting-cell preparation were conducted at room temperature.

Analytical methods

Biomass concentrations were determined photometrically as the optical density at a wavelength of 450 nm (Libra S11 spectrophotometer, Biochrom Ltd., Cambridge, UK). One OD450 unit corresponds to 0.166 gCDW L-1 for E. coli [49] and 0.186 gCDW L-1 for P. taiwanensis [50], respectively.

Monitoring of protein synthesis was performed by harvesting 80 μg of cell dry weight (CDW) from cultures for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to Laemmli [51]. Proteins extracted from 15 μgCDW were loaded per lane and stained with Coomassie Brillant Blue R-250. PageRuler Prestained Protein Ladder (Thermo Fisher Scientific, Waltham, MA, USA) was used as reference.

Testosterone and respective product (2β- and 15β-hydroxytestosterone) concentrations were determined via HPLC using a Dionex Ultimate 3000 system (Thermo Fisher Scientific) equipped with a Syncronis C18 column (150 x 2.1 mm, 3 μm particle size, Thermo Fisher Scientific) and an UV detector operating at 245 nm for steroid detection. After injection of 5 μL sample, steroids were eluted at a column oven temperature of 40°C with 55% acetonitrile in ultrapure water as a mobile phase at a flow rate of 0.5 mL min-1. Quantification was based on peak areas and calibration curves prepared with commercially available standards.

Progesterone and 16α-hydroxyprogesterone were quantified using the same HPLC system equipped with an Accucore C18 column (150 x 3 mm, 2.6 μm particle size, Thermo Fisher Scientific). An eluent consisting of 50% acetonitrile in ultrapure water was used at a flow rate of 0.6 mL min-1. Column oven temperature, sample volume, detection, and quantification were as described above.

Results and discussion

In our previous work, E. coli BL21-Gold(DE3)_pETM11-ksa14m-alkL carrying the BM3 variant KSA14m and the hydrophobic outer membrane pore AlkL has been developed (S1A Fig), enabling high-rate testosterone hydroxylation to 15β-hydroxytestosterone as main product (85%) [17]. Poor operational stability, however, was observed for this biocatalyst in the nitrogen-deprived resting-cell state [22]. In this study, we investigate various strategies to counteract whole-cell biocatalyst destabilization with the ultimate goal to enable high process durability and thus efficiency.

Relieving nitrogen limitation does not stabilize testosterone hydroxylation rates

Approaches based on resting (i.e., metabolically active non-growing) cells decouple growth and biocatalyst synthesis from the production phase. Their application allows growth-independent investigation and optimization of desirable reactions, can minimize side reactions, and enables the identification of potential limitations of the overall performance [18, 30, 52]. Compared to growing cells, resting cells have proven beneficial for redox biotransformations with respect to specific activities [29, 30, 33, 53, 54] as well as reusability [55]. However, establishing the resting-cell state represents a transition from the availability of all essential nutrients to a limitation of one or more nutrients [31]. Beside respective technical efforts, this involves changes in microbial physiology including intracellular metabolite concentrations and metabolic fluxes [56], which depend on the type of limitation and ultimately affect heterologous protein synthesis. For example, nitrogen-deprived E. coli cells displayed lower glucose uptake as well as pyruvate and acetate secretion rates than magnesium-limited cells [33, 52]. Consequently, the type of nutrient limitation is decisive for resting-cell phenotypes. Omitting nitrogen from the biotransformation medium is prone to effect a limited amino acid and protein synthesis capacity [57], putatively leading to poor stability of (heterologous) enzyme levels/activities under production conditions as observed for the investigated testosterone-hydroxylating whole-cell biocatalyst. Furthermore, Fe(III) constitutes an essential component of the heme center located in the active site of CYP450s and may become limiting [7]. Interestingly, employing resting cells in a complete growth medium lacking only magnesium has been reported to stabilize limonene formation by engineered E. coli compared to their application in nitrogen-deprived KPi buffer [33]. Thereby, the application of complete M9 medium lacking only nitrogen did not result in differences compared to KPi buffer with glucose. Applying M9 medium just lacking magnesium did, however, not significantly improve nor stabilize specific KSA14m-based testosterone hydroxylation rates, which still dropped by 30-36% within the first 30 min of the reaction (Fig 1A). Also inducer addition to resting cell media did not lead to a stabilization, whereas this has been reported to partially relieve enzyme instability issues in previous studies [28, 33]. Relative KSA14m levels were stable for 1 h but not detectable after 24 h of biotransformation (Fig 1B). This is in stark contrast to AlkL, for which the SDS-PAGE band even intensified after 24 h with the inducer present under magnesium-limited conditions. The BM3 variant obviously decayed under biotransformation conditions, although gene expression from the same operon still occurred to a considerable extent. Altogether, the poor KSA14m-based biocatalyst stability could not be alleviated by facilitating protein re-synthesis via nitrogen supply and magnesium limitation or continuous induction. Generally, biocatalytic activities of resting recombinant cells often have been observed to decrease steadily, e.g., due to limited enzyme stability and resynthesis [33, 5861]. CYP450 resynthesis may become limiting when biosynthetic and thus enzyme synthesis capacities are down-regulated in a non-growing state, gene expression profiles are altered [62], and cellular resource demands increase due to toxic effects of enzymes and product [30]. Therefore, cells growing in media containing all necessary components for (re-)synthesis often convey superior stability, possibly favoring this biocatalyst configuration for process setups.

Fig 1. Biotransformations with resting E. coli BL21-Gold(DE3)_pETM11-ksa14m-alkL cells limited in either nitrogen (N) or magnesium (Mg).

Fig 1

Microorganisms were grown in M9 medium containing 0.5% (w/v) glucose. Resting cells were prepared 5 h after induction, and biotransformations were performed as described in Materials and Methods. (A) Specific testosterone hydroxylation activity time courses for cells suspended in either N-free KPi buffer or Mg-free M9 medium, optionally supplied with 0.1 mM IPTG and 0.5 mM 5-aminolevulinic acid (inducer, dashed lines). Data points represent average values and standard deviations of biological duplicates. (B) SDS-PAGE analysis shows KSA14m (119 kDa, black arrow) and AlkL (23 kDa, grey arrow) levels during biotransformations under the indicated conditions: N-deprived cells in absence or presence of substrate (testosterone), Mg-limited cells with substrate in absence or presence of IPTG and 5-aminolevulinic acid (inducer and heme building block).

Growing-cell biotransformation allows continuous KSA14m synthesis, but does not lead to activity stabilization

In contrast to resting cells, growing cells enable efficient (re-)synthesis of cells, enzymes, and energy/redox carriers [18, 63]. This biocatalyst format thus is considered favorable for the handling of instable enzymes as well as biocatalysis-related stress, such as substrate- and/or product-related toxicity, inhibition, or oxidative stress [30, 34, 64]. As this becomes especially important for catalysis by instable CYP450s, we studied the catalytic performance of growing E. coli BL21-Gold(DE3)_pETM11-ksa14m-alkL cells (Fig 2).

Fig 2. Biotransformations with growing E. coli BL21-Gold(DE3)_pETM11-ksa14m-alkL cells.

Fig 2

Bacteria were cultivated in M9 medium with 0.5% (w/v) glucose, induced with 0.1 mM IPTG, harvested before and after 5 h of induction, and resuspended in fresh M9 medium containing 1% (w/v) glucose, 0.1 mM IPTG, and 5-aminolevulinic acid to a biomass concentration of 1 gCDW L-1. Ten mL liquid volume were transferred to 100 mL baffled, screw-capped flasks and equilibrated for 10 min at 30°C. Biotransformations were started by addition of 1 mM testosterone. (A) Time courses of specific testosterone hydroxylation activities (solid black lines), cell concentrations (dashed black lines), and steroid concentrations (dashed grey lines; products referring to the sum of 2β- and 15β-hydroxytestosterone) with 5 h of induction before and induction simultaneously to the biotransformation start. Average values and standard deviations were calculated from two biological replicates. (B) SDS-PAGE analyses showing heterologous KSA14m (119 kDa, black arrows) and AlkL (23 kDa, grey arrows) levels at different time points after biotransformation start.

Biotransformations initialized after 5 h of induction displayed initial specific product formation rates of 14.1 ± 0.9 U gCDW-1 (Fig 2A, left), which accounted for only 31% of rates obtained with resting cells prepared after the same induction time (46.0 ± 0.1 U gCDW-1, Fig 1A). Similar findings have been reported for recombinant E. coli capable of styrene epoxidation [30], cyclohexanone Baeyer-Villiger oxidation [54], naphthalene oxidation [53], or P. taiwanensis harboring an enzyme cascade producing 6-hydroxyhexanoic acid from cyclohexane [28]. Lower growing-cell activities typically result from a stronger competition of enzyme synthesis and metabolic demands of the reaction with demands for cellular maintenance and biomass formation [18, 29]. However, opposite observations exist for styrene-epoxidizing P. taiwanensis VLB120 strains [6567]. In contrast to resting-cell biotransformations, KSA14m levels were however stable for 24 h of biotransformation (Fig 2B, left), confirming continuous enzyme synthesis by growing cells. Despite stable KSA14m levels and available testosterone, specific activities declined rapidly (Fig 2A, left). Product formation was detected for 2 h of biotransformation, which was not significantly longer compared to resting cells [22]. For cells induced simultaneously with substrate addition, specific activities slowly increased (Fig 2A, right) correlating with increasing KSA14m levels (Fig 2B, right). A maximum of 3.0 ± 0.1 U gCDW-1 was reached after 1.5 h, followed by an activity decrease despite stable KSA14m levels and sufficient testosterone availability for at least 2 h of biotransformation. The weak product inhibition of the system [22] likely can be excluded as the cause for the activity decrease, which may rather be caused by the loss of heme and/or FMN/FAD as the prosthetic groups of the oxygenase and/or reductase domains of CYP450 BM3, respectively. These aspects remain to be evaluated in future studies. Obviously, KSA14m experienced a similar inactivation in growing as in resting cells, which could not be alleviated by enzyme resynthesis in growing cells. After 5 h of induction and with the same cell and initial testosterone concentrations, resting cells reached clearly higher activities leading to faster initial product accumulation (S2 Fig). The higher product titer reached within 1 h correspond to a superior space-time yield of 0.25 vs. 0.15 g L-1 h-1. Resting cells therefore remained the format of choice for further studies.

Cultivation medium and expression strategies influence initial whole-cell activity, but not its stability

Beside product inhibition, we previously proposed uncoupling and ROS formation as a critical factor possibly affecting biocatalyst stability [22] either in terms of cell toxification or enzyme deactivation [2426]. The latter may manifest in active site destruction, as it has been reported for the heme cofactor in CYP450s [68, 69]. We first investigated effects of medium composition and differential ksa14m expression, in order to foster functional enzyme synthesis.

As previously demonstrated for a 6-hydroxyhexanoic acid-producing P. taiwanensis, medium composition is a core factor influencing cell physiology and catalytic performance [28]. Effects of cultivation in different standard minimal media, i.e., M9, M9*, and RB [40, 48], on E. coli BL21-Gold(DE3)_pETM11-ksa14m-alkL were investigated in terms of specific growth rate, heterologous protein synthesis, and specific testosterone hydroxylation activities. Compared to M9, M9* contains the three-fold concentration of phosphate salts resulting in higher buffering capacity, whereas RB is characterized by increased ammonium concentrations and intermediate phosphate concentrations (S3 Table).

The specific growth rate did not considerably differ in M9 and RB media and was 18% lower in M9* medium (Fig 3A), while induction in M9* medium led to higher relative KSA14m levels compared to M9 and RB media (Fig 3B). Initial testosterone hydroxylation activities obtained in the resting cell format were however highest after growth in M9 medium, being 24 and 45% lower after growth in RB and M9* medium, respectively (Fig 3C). Thereby, variations in cell physiology depending on the growth medium applied may play a role, possibly involving differences in metabolic by-product accumulation and respective inhibitory effects on bacterial growth [70, 71]. Additionally, changed metabolic fluxes may influence the availability of resources for (heterologous) enzyme synthesis and catalysis, which in turn can result in differing amounts of functional enzyme, even when the overall levels of a specific enzyme remain similar. Altogether, the biocatalyst performance obtained upon cultivation in M9 medium exceeded that achieved with other minimal media. In all cases, however, activities decreased rapidly during resting-cell biotransformations. These observations again indicate that high oxygenase (KSA14m) levels do not necessarily result in high activities. This also has been observed in other studies and was connected to negative effects on the host cell physiology, which could be overcome by fine-tuning of oxygenase levels in the cell [17, 29, 72, 73].

Fig 3. Performance of E. coli BL21-Gold(DE3)_pETM11-ksa14m-alkL depends on cultivation medium composition.

Fig 3

Cells grown and induced in M9, M9*, or RB medium containing 0.5% (w/v) glucose as carbon and energy source. Specific growth rates (A), KSA14m (119 kDa, black arrow) and AlkL (23 kDa, grey arrow) levels (SDS-PAGE, B) and resting-cell activity courses after 5 h of induction in nitrogen-deprived KPi buffer containing 1% (w/v) glucose (C) were analyzed as described in Materials and Methods. Average values and standard deviations of biological duplicates are shown.

The construct pETM11-ksa14m-alkL used so far features the lacI-PT7-based regulatory system (S1A Fig) allowing fast and strong expression of ksa14m and alkL. Beside differences in the molecular environment in host strains compared to the wildtype strain possibly affecting functional expression and catalysis [11], plasmid maintenance and heterologous gene (over)expression may impose a metabolic burden [27]. Other critical factors complicating stable and functional CYP450 synthesis include protein folding and heme incorporation. Further, cofactor regeneration via the cellular metabolism may not keep up with the high catalytic rates enabled by the enzyme [74], and high oxygenase activities may lead to enforced ROS formation, which can affect both host and oxygenase stability [24, 73, 75]. Taken together, fine-tuning of ksa14m expression on the genetic level appears promising to stabilize testosterone hydroxylation by recombinant E. coli [36]. Recently, a doubling of CYP450-mediated cyclohexane hydroxylation activity has been achieved by regulatory system engineering in recombinant P. taiwanensis VLB120 [72]. We thus tested different expression systems and inducer concentrations to vary gene expression rates and levels and investigate respective effects on whole-cell biocatalyst activity and stability. New vectors were based on the pCOM10 plasmid backbone carrying regulatory systems based on IPTG-inducible lacI-PlacUV5 or lacIq-Ptac or DCPK-inducible alkS-PalkB (S1B–S1D Fig) [4446]. These all have in common a lower promoter strength than the so far applied PT7 promoter (PT7 > Ptac ≈ PalkB > PlacUV5) and are considered as easier titratable by varying the concentration of respective inducers [7679]. These characteristics allow the investigation of whole-cell biocatalyst performance upon variation of transcription and ultimately expression levels. The resulting constructs plac-ksa14m-alkL, ptac-ksa14m-alkL, and palk-ksa14m-alkL were introduced and tested in E. coli BL21-Gold(DE3).

Applying inducer levels known to effect varying induction strength, the highest initial activities were achieved with low inducer concentrations with all constructs whereas stronger induction led to a 34–79% lower initial activity depending on the construct applied (Fig 4). At low inducer concentrations, the constructs ptac-ksa14m-alkL and pETM11-ksa14m-alkL allowed the fastest growth (μ = 0.42 h-1) and the highest initial activities (32.6 ± 0.2 and 45.2 ± 0.9 U gCDW-1, respectively). The hampered and non-exponential growth observed for most recombinant strains at elevated inducer concentrations indicated a significant metabolic burden, likely imposed by high gene expression rates competing with energy demands for growth [27]. In the case of plac-ksa14m-alkL, growth also was impaired at low IPTG concentrations, possibly due to metabolic burden related to the maintenance of this particular plasmid [80]. Interestingly, relative KSA14m levels remained unaffected by inducer titration (S3A, S3B and S3D Fig) except for ptac-ksa14m-alkL, with which higher IPTG concentrations led to higher relative oxygenase levels (S3C Fig). The mere increase in enzyme amount, however, was not associated with higher whole-cell activities (Fig 4C). Especially upon strong induction, a large CYP450 fraction likely was not appropriately processed in terms of folding and/or heme incorporation. Activity further may have been limited by NADPH supply via the stressed cell metabolism as well as uncoupling-related effects on cell physiology and enzyme performance [27]. Altered expression systems and inducer concentrations may also have affected active AlkL levels provoking positive or negative effects on whole-cell biocatalyst performance in terms of improved substrate availability or toxic intracellular substrate and/or product titers, respectively [17, 8183].

Fig 4. Effects of expression system and inducer concentration on the performance of E. coli BL21-Gold(DE3) strains synthesizing KSA14m and AlkL.

Fig 4

Left and right columns show courses of growth and specific resting-cell testosterone hydroxylation activities, respectively, upon ksa14m and alkL expression under control of different regulatory systems (S1 Fig) and with different inducer concentrations. (A) AlkS-PalkB-based system induced with DCPK; (B) LacI-PlacUV5-based system induced with IPTG; (C) LacIq-Ptac-based system induced with IPTG; (D) LacI-PT7-based system either uninduced or induced with IPTG. Cells were grown in M9 medium containing 0.5% (w/v) glucose and induced for 5 h, followed by cell harvesting and resting-cell biotransformations performed as described in Materials and Methods in nitrogen-deprived KPi buffer containing 1% (w/v) glucose with a cell concentration of 1 gCDW L-1 unless indicated otherwise. Average values and standard deviations of two biological replicates are given.

However, specific activities were instable for all tested strains independently of inducer concentration and expression system used (Fig 4, right column). As the activity drop for whole-cell biocatalysts with high initial activity can be due to fast testosterone depletion [22], the effect of substrate availability was further investigated by reducing the biocatalyst concentration applying the same initial testosterone concentration (1 mM), which ensured an increased availability of both testosterone and O2. Initial activities were the same, excluding O2 limitation as a critical factor (Fig 4B and 4C). For the strain carrying ptac-ksa14m-alkL, the instability was largely preserved (Fig 4C). Interestingly, the strain carrying plac-ksa14m-alkL exhibited a higher stability with 10-fold reduced cell concentration (Fig 4B, right column). A similar, but less pronounced stabilization of testosterone hydroxylation rates upon biocatalyst concentration decrease also has been observed for E. coli carrying pETM11-ksa14m-alkL [22], which however showed significantly higher initial activities (Fig 4B and 4D). In this respect, the mentioned weak product inhibition and limited testosterone availability have to be considered [22], being less prominent at low biocatalyst concentration and thus product accumulation.

In summary, the tested variations of expression system and inducer concentrations did not result in significantly improved initial biocatalyst activity or stability (except for plac-ksa14m-alkL), but showed that the construct pETM11-ksa14m-alkL enables comparatively efficient expression along with fast growth. Further attempts to stabilize the activity via genetic engineering should follow a holistic and systematic engineering approach involving the dissection of effects related to transcription (via promoter), translation (via ribosomal binding site), and gene dosage (via origin of replication), as it has been performed for CYP450-catalyzed cyclohexane hydroxylation [72].

Protein engineering with focus on uncoupling

Protein engineering has been reported to be a valuable option to increase turnover numbers and (thermo-)stability of CYP450s, including BM3 [38, 84]. Various enzyme properties such as catalytic rate, specificity, and stability can be addressed either by rational design or directed evolution. Testosterone-hydroxylating BM3 variants were generated by engineering the key active site residue F87, i.e., by introducing the smaller amino acid alanine, thereby vacating space for the bulky non-native substrate testosterone [16]. However, a typical side effect of this approach is uncoupling, occurring upon suboptimal positioning of the substrate and/or binding of the product molecule in the active site [8587]. Compared to wildtype BM3, converting natural substrates highly coupled to NADPH oxidation (93–96% for long-chain fatty acids) [88, 89], the single mutant F87A indeed exhibits a poor coupling efficiency of 6.5% for testosterone hydroxylation [16]. Uncoupling-related effects on whole-cell biocatalyst efficiency include an increased O2 and NADPH demand and ROS-related enzyme/cell inactivation/destabilization [4, 5, 18, 73, 90]. Mutations improving the substrate fit in the active site have proven successful to reduce uncoupling, e.g., for 2-hydroxy biphenyl 3-monooxygenase [91] or CYP101 [92]. Also the coupling efficiency of BM3 variants has been improved, with the optimization of propane-hydroxylating variants as prime example (P450PMO) [93].

Despite its tendency towards uncoupling after amino acid substitution, further mutation of F87A was not feasible as it enables testosterone conversion in the first place. Alternatively, mutation of position 82 has been reported to foster uncoupling [94], which is why we evaluated KSA14m variants with the original alanine being reintroduced at that position. For P450PMO, further mutations were found to enhance coupling efficiency, whereby the single mutation L188P caused the largest effect [37]. Based on these promising results, we constructed three new KSA14m variants that either carried single mutations, M82A (KSA14m_M82A) or L188P (KSA14m_L188P), or were equipped with stabilizing mutations of P450PMO (L52I, A184V, I366V, G443A and D698G = KSA14mutations) [37].

Growth of E. coli BL21-Gold(DE3) strains harboring respective variants and AlkL was not affected by these mutations (S4 Fig). During resting-cell biotransformations of testosterone, strains with KSA14mutations displayed exactly the same activity levels and instability as those carrying KSA14m (Fig 5A). Interestingly, the single mutation M82A caused a 34% reduced initial activity, indicating its significant role in testosterone hydroxylation, while L188P did not influence initial rates. M82A did not stabilize activities, whereas L188P appeared to cause a slightly slower activity decrease (Fig 5A). To investigate biotransformation-independent whole-cell biocatalyst stability, the normally applied equilibration time under reaction conditions prior to biotransformation start (0.25 h) was prolonged. Initial specific testosterone hydroxylation activities of all BM3 variants declined with extended pre-incubation, revealing a rather high biotransformation-independent instability (Fig 5B) as previously reported for the original whole-cell biocatalyst harboring KSA14m [22]. In contrast to the activity drop during biotransformation, the fastest decrease was observed for the L188P variant.

Fig 5. Effect of amino acid exchanges in KSA14m on testosterone hydroxylation activity and stability.

Fig 5

E. coli BL21-Gold(DE3) cells carrying pETM11 equipped with genes encoding different KSA14m variants and AlkL were grown in M9 medium containing 0.5% (w/v) glucose. Resting cell preparation 5 h after induction with 0.1 mM IPTG and biotransformations were performed as described in Materials and Methods in nitrogen-deprived KPi buffer containing 1% (w/v) glucose. (A) Time courses of specific testosterone hydroxylation activities (solid lines) and testosterone concentrations (dashed lines). (B) Initial activities (5 min) after different equilibration times under reaction conditions. Average values and standard deviations of biological duplicates are given.

In conclusion, the chosen mutations did not significantly stabilize whole-cell testosterone hydroxylation activities. It has to be considered that most mutations tested improved coupling of a BM3 variant optimized for the substrate propane [37], which obviously differs from testosterone in terms of bulkiness and polarity. Future engineering attempts thus may focus on improved testosterone binding, as low KM values have been found to correlate with high coupling efficiencies [93], and benefit from the recent development of computational methods capable of three-dimensional protein structure prediction from amino acid sequences, such as AlphaFold [95].

P. taiwanensis as host organism for CYP450 BM3 catalysis

Intrinsic features of the heterologous host organism can crucially impact the functional synthesis and stability of recombinant enzymes. E. coli lacks intrinsic CYP450 genes, which minimizes cross reactivities. However, despite the existence of hemoproteins like cytochrome bc, heme synthesis in E. coli is not very efficient, which can hamper active site buildup in KSA14m. In contrast, pseudomonads possess the intrinsic ability to efficiently synthesize heme, which makes the addition of a heme precursor (such as 5-aminolevulinic acid) unnecessary. The strain P. taiwanensis VLB120 represents a highly interesting host strain as it can tolerate high solvent levels and provides a high metabolic capacity to support oxygenase catalysis also at high cell densities and also for CYP450s [65, 67, 96, 97]. KSA14m-catalyzed testosterone hydroxylation was thus investigated using P. taiwanensis VLB120_Strep. To this end, pCOM10 vectors proven suitable for heterologous oxygenase synthesis in various E. coli [44, 98] as well as Pseudomonas strains [45, 46] and equipped with ksa14m were used. Optionally, the plasmids contained genes encoding hydrophobic outer membrane proteins, for which a facilitated testosterone uptake into E. coli has been demonstrated previously [17]. Tested candidates comprised AlkL, TodX (native toluene uptake protein from Pseudomonas putida F1 [99]), and FhuA Δ1–160 (truncated importer for ferric hydroxamate from E. coli [100]). Growth, protein synthesis, and specific activities were evaluated for P. taiwanensis VLB120_Strep strains harboring palk-ksa14m-alkL, plac-ksa14m, plac-ksa14m-alkL, ptac-ksa14m-alkL, plac-ksa14m-fhuAΔ1–160, or plac-ksa14m-todX (Fig 6).

Fig 6. P. taiwanensis VLB120_Strep hosting the heterologous synthesis of KSA14m and different hydrophobic outer membrane pores.

Fig 6

(A) Growth of P. taiwanensis VLB120_Strep strains equipped with different plasmids for KSA14m and hydrophobic outer membrane pore synthesis in M9 medium containing 0.5% (w/v) glucose compared to the wild type (WT). Data points represent average values and standard deviations of biological duplicates. Heterologous gene expression was induced with 0.0025% (v/v) DCPK or 0.1 mM IPTG. (B) Recombinant KSA14m levels (119 kDa, black arrow) were examined via SDS-PAGE 5 h after induction for the wild type (1) and strains harboring either palk-ksa14m-alkL (2), plac-ksa14m (3), plac-ksa14m-alkL (4), plac-ksa14m-fhuAΔ1-160 (5), or plac-ksa14m-todX (6).

Cells equipped with ptac-ksa14m-alkL did not grow at all in LB precultures. The other plasmid-containing strains grew more slowly than the plasmid-free wild type, even before induction (Fig 6A), indicating leaky gene expression. A second exponential phase started ~1 h after induction. For the palk-ksa14m-alkL strain, KSA14m was not visible on SDS-PAGE gels (Fig 6B), and testosterone hydroxylation was not detected. With all other plasmids (based on pCOM10_lac), low KSA14m levels (Fig 6B) and low specific product formation rates (1.2–2.4 U gCDW-1) were observed. The similar activities with and without pores are not surprising since testosterone uptake only becomes limiting with higher intracellular steroid conversion activities. It however remains unclear, if outer membrane proteins were synthesized (not visible on SDS-PAGE gels, see Fig 6B in S1 Raw images). Carrying the same broad host range plasmid plac-ksa14m-alkL, P. taiwanensis VLB120_Strep showed 14-fold lower specific activities than E. coli BL21-Gold(DE3), rendering the latter by far superior for testosterone hydroxylation. Therefore, employing E. coli strains featuring improved heme uptake or production may constitute an interesting option for CYP450 BM3-based steroid hydroxylation [101103]. This however does not dismiss pseudomonads as hosts for biocatalytic steroid hydroxylations, since the systematic evaluation of other expression vectors may still improve their performance with regard to growth, heterologous protein synthesis, and catalytic activity [72].

Alternative steroid-hydroxylating CYP450s display higher stability but low activity

Although initial specific steroid conversion rates achieved with engineered BM3 variants proved to be superior to those reported for native steroid-hydroxylating CYP450s [17], the latter showed better stability [20, 21, 104, 105]. CYP106A2 from B. megaterium ATCC13368 (15β-hydroxylation of testosterone) and CYP154C5 from Nocardia farcinica IFM10152 (16α-hydroxylation of progesterone) exhibited the most promising activities [20, 21], surpassing those of mammalian CYP450s or other bacterial representatives [17]. In contrast to self-sufficient CYP450 BM3, these oxygenases depend on additional redox proteins such as the compatible putidaredoxin reductase (PDR, encoded by camA) and putidaredoxin (Pd, encoded by camB). Most oxygenases constitute multi-component systems, which can involve a limitation by the electron transfer to the active site. In contrast, self-sufficient systems experience high electron pressure on the active site [24, 73, 75], which can foster uncoupling reactions and concomitant ROS formation. Thus, we evaluated specific activities of cells containing CYP106A2 or CYP154C5 together with PDR and Pd and investigated respective stabilities.

In the first approach, CYP450 genes were combined with camA, camB, and optionally alkL in one single operon under control of the LacI-PT7-based regulatory system on the pETM11 plasmid (S5 Fig, one plasmid strategy). Whereas cloning was not successful with cyp106a2, vectors pET154-camAB and pET154-camAB-alkL carrying cyp154c5 were successfully established in E. coli BL21-Gold(DE3). Specific growth rates were not considerably hampered upon induction of recombinant gene expression in M9 medium (μ = 0.40–0.43 h-1, S6A Fig). High-level synthesis of CYP154C5 and AlkL was detected when expected (S6B Fig). A 39 kDa protein band intensified after induction and likely represents PDR, as this band also became visible after induction with a plasmid carrying only the PDR and Pd genes (pACYC-camAB, S9 Fig). The rather small Pd (11 kDa) was not detectable in the SDS-PAGE setup applied. In accordance with previous studies summarized in Bertelmann et al. [17], specific progesterone hydroxylation rates were stable over 2 h but very low (~1 U gCDW-1, Fig 7). Since the presence of AlkL did not improve CYP154C5-based whole-cell steroid conversion rates, we tested, if AlkL at all can facilitate progesterone uptake by applying KSA14m to catalyze this reaction as previously reported [16]. E. coli cells equipped with KSA14m and AlkL indeed displayed 4.2-fold higher initial product formation rates (up to 14 U gCDW-1) than cells without AlkL (S7 Fig). Thus, an uptake limitation only becomes relevant, if high intracellular steroid conversion activities are established, which was not the case with CYP154C5.

Fig 7. Resting-cell biotransformations with E. coli BL21-Gold(DE3) cells carrying pETM11 with cyp154c5, camA, camB (and optionally alkL)—One plasmid strategy.

Fig 7

Time courses of specific progesterone hydroxylation activities (solid lines) and product concentrations (dashed lines) are depicted. Bacteria were cultivated in M9 medium containing 0.5% (w/v) glucose. Resting cells were prepared 5 h after induction with 0.1 mM IPTG and applied as described in Materials and Methods. Average values and standard deviations of biological duplicates are presented.

Maintaining a large plasmid and expressing 4 genes from one single operon can cause expression issues and hamper functional expression. Consequently, genes were located on two separate plasmids in a second approach. The respective CYP450 gene and optionally alkL were placed on pETM11 or pCOM10_tac (S5B Fig), leading to eight different plasmids carrying cyp154c5 or cyp106a2 and optionally alkL. As second plasmid, pACYC was equipped with camA and camB giving rise to pACYC-camAB (S5A Fig), of which the pA15 origin is compatible with both pMB1 and ColE1 of pETM11 and pCOM10_tac, respectively.

The only slight decrease of specific growth rates compared to the wild type (0.43 h-1, Table 2) indicated that E. coli BL21-Gold(DE3) can cope with the metabolic burden imposed by the presence of two plasmids and the simultaneous expression of heterologous genes (S8 Fig). For strains carrying the cyp106a2 gene, no or only trace amounts of product were detected after 20 h of biotransformation (Table 2). CYP106A2 was not observed on SDS gels at the expected size (45 kDa), but may be represented by a thin band at ~60 kDa which intensified after induction (S9B–S9D Fig). In contrast, SDS-PAGE analyses demonstrated clear bands for CYP154C5 (S9A, S9C and S9D Fig). AlkL was observed when expected and also bands for PDR and Pd were detected, whereas significant leaky expression occurred in most cases. Initial resting-cell activities obtained with CYP154C5 were slightly higher than those obtained with one plasmid, with pET154 enabling a 3-fold increase (Table 2). However, these testosterone hydroxylation rates were still low, not subject to AlkL-mediated improvement, and not of special interest for industrial implementation.

Table 2. Specific growth rates and specific activities of E. coli BL21-Gold(DE3) strains carrying genes encoding alternative CYP450sa.

Plasmid backbone pCOM10_tac pETM11
Genes cyp154c5 cyp154c5, alkL cyp106a2 cyp106a2, alkL cyp154c5 cyp154c5, alkL cyp106a2 cyp106a2, alkL
Resulting plasmid ptac154 ptac154A ptac106 ptac106A pET154 pET154A pET106 pET106A
Specific growth rate [h-1] 0.339 ± 0.002 0.336 ± 0.001 0.366 ± 0.002 0.346 ± 0.002 0.414 ± 0.001 0.416 ± 0.003 0.424 ± 0.006 0.412 ± 0.001
Resting-cell activity [U gCDW-1] 1.72 ± 0.13 (5 min) 1.45 ± 0.03 (5 min) no product detected for 20 h ~45 μM detected after 20 h 3.32 ± 0.11 (5 min) 1.58 ± 0.01 (5 min) no product detected for 20 h ~50 μM detected after 20 h

a Plasmids based on either pCOM10_tac or pETM11 were introduced to provide cyp154c5 or cyp106a2 and optionally alkL. All strains harbored pACYC-camAB encoding PDR and Pd necessary for electron delivery.

Conclusion

Testosterone hydroxylation can be catalyzed at exceptionally high rates by whole-cell biocatalysts carrying the BM3 variant KSA14m and the uptake facilitator AlkL, but suffers from an inherent instability. In order to optimize biocatalyst stability, this work evaluated a wide variety of approaches proven successful for processes employing other oxygenases (Table 3). Different biocatalyst formats and enzyme variants were tested and conditions for heterologous enzyme synthesis were varied in terms of cultivation medium, inducer concentration, expression system, and microbial host. None of these approaches however improved operational stability or initial specific activity. Whereas these findings provide valuable guidance for researchers tackling similar CYP450 stability issues, an activity comparison of the BM3-based whole-cell biocatalysts with natively steroid-hydroxylating CYP450s and suitable redox partners in equivalent biocatalyst and reaction setups qualified the former as clearly superior. BM3 stabilization via protein engineering, especially substrate affinity/positioning, is considered to remain as the most promising approach given the large and fast developing tool set for structure prediction and modification.

Table 3. Summary of strategies investigated to stabilize KSA14m-catalyzed testosterone hydroxylation using whole-cell systems and their effect on initial specific activity and stability.

Strategy Aim Effect on initial specific activity Effect on stability of activity
Biotransformation with magnesium-deprived resting cells in a complete growth medium fostering capacity for functional KSA14m (re-)synthesis during biotransformation by supplying nitrogen and iron no effect no effect
Presence of inducer during resting-cell biotransformation fostering KSA14m (re-)synthesis by induction of gene transcription during biotransformation no effect no effect
Biotransformation using growing cells efficient (re-)synthesis of cells, enzymes, and energy/redox carriers during biotransformation
superior handling of biocatalysis-related stress
3-fold reduction compared to resting cells no effect
Variation of cultivation media for heterologous protein synthesis
(resting-cell biotransformation)
variation in cell physiology leading to higher levels of functional KSA14m level after cultivation in different media:
M9 > RB > M9*
no effect
Variation of inducer concentration for heterologous protein synthesis
(resting-cell biotransformation)
reduction of expression to achieve:
• reduction of metabolic burden
• higher share of functional enzyme (protein folding, heme incorporation)
• lower KSA14m levels decreasing cofactor demand and possibly uncoupling
lowest inducer concentrations enabled highest activities no effect
Variation of expression system for heterologous protein synthesis
(resting-cell biotransformation)
level with different regulatory systems:
lacI-PT7 > lacIq-Ptac
> lacI-PlacUV5 > alkS-PalkB
no effect, except for slight stabilization with lacI-PlacUV5 regulatory system at low biomass density
KSA14m engineering
(resting-cell biotransformation)
reduction of possible uncoupling-related instability no effect, except for 1.5-fold reduction with M82A no improvement, fastest decrease with L188P variant
Pseudomonas taiwanensis as host organism
(resting-cell biotransformation)
supporting functional KSA14m synthesis by intrinsic heme maturation apparatus significantly lower not investigated

Supporting information

S1 Table. Primer sequences and PCR templates used for the construction of the plasmids used in this study.

(PDF)

pone.0309965.s001.pdf (307.6KB, pdf)
S2 Table. Components and settings of site-directed mutagenesis PCR to introduce M82A and L188P amino acid exchanges into KSA14m.

(PDF)

pone.0309965.s002.pdf (110.8KB, pdf)
S3 Table. Composition and preparation of minimal media used in this study.

(PDF)

pone.0309965.s003.pdf (15.7KB, pdf)
S1 Fig. Genetic constructs applied for co-expression of the genes encoding the 6xHis-tagged BM3 variant KSA14m and the hydrophobic outer membrane protein AlkL in a bicistronic operon under control of different expression systems.

Heterologous gene expression was either realized via (A) the T7 promoter (PT7), (B) the alkB promoter (PalkB), (C) the lacUV5 promoter (PlacUV5), or (D) the tac promoter (Ptac) based on either LacIq (A, C, D) or AlkS (B) as regulators. The creation of plasmids pETM11-ksa14m-alkL (A), palk-ksa14m-alkL (B), plac-ksa14m-alkL (C), and ptac-ksa14m-alkL (D) is explained in S1 Table.

(JPG)

pone.0309965.s004.jpg (408.1KB, jpg)
S2 Fig. Courses of product formation during biocatalytic testosterone hydroxylation with resting and growing E. coli BL21-Gold(DE3) cells.

Microorganisms were cultivated in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG. Biotransformations were conducted as described in the Materials and Methods Section. Average values and standard deviations of two biological replicates are shown.

(TIF)

pone.0309965.s005.tif (507.4KB, tif)
S3 Fig. SDS-PAGE analyses for E. coli BL21-Gold(DE3) strains producing KSA14m (119 kDa, black arrows) and AlkL (23 kDa, grey arrows) under control of different gene expression systems (see S1 Fig) and with different inducer concentrations.

Microorganisms were cultivated in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced in the early exponential phase. (A) AlkS-PalkB-based regulatory system, induced with different DCPK concentrations. (B) LacI-PlacUV5-based expression system, induced with different IPTG concentrations. (C) LacIq-Ptac-based expression system, induced with different IPTG concentrations. (D) LacI-PT7-based regulatory system, either uninduced or induced with different IPTG concentrations.

(JPG)

pone.0309965.s006.jpg (2.6MB, jpg)
S4 Fig. Growth of E. coli BL21-Gold(DE3) strains carrying pETM11 equipped with alkL and either the original ksa14m gene or variants thereof (ksa14mutations, ksa14m_M82A, ksa14m_L188P).

Bacterial cells were grown in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG in the early exponential phase. Average values and standard deviations of two biological replicates are given.

(TIF)

pone.0309965.s007.tif (190.2KB, tif)
S5 Fig. Genetic constructs applied for co-expression of genes encoding alternative steroid hydroxylation systems.

Necessary genes encoded either CYP154C5 or CYP106A2 (cyp), redox partner proteins (camA for putidaredoxin reductase, PDR, and camB for putidaredoxin, Pd), as well as the hydrophobic outer membrane protein AlkL (alkL). I) One plasmid strategy: one vector for the synthesis of 6xHis-tagged CYP154C5, PDR, Pd, and AlkL under control of the LacI-PT7-based expression system. II) Two plasmid strategy: cyp/alkL and camA/camB were expressed from two separate plasmids. Final bacterial strains always contained plasmid A (pACYC-camAB) carrying camA and camB under control of two separate T7 promoters. In addition, the cells harbored either plasmid B1 or B2 carrying the respective cyp genes and alkL under control of PT7 (B1) or Ptac (B2). Plasmid construction is detailed in S1 Table.

(JPG)

pone.0309965.s008.jpg (502.6KB, jpg)
S6 Fig. Performance of E. coli BL21-Gold(DE3) cells carrying pETM11 equipped with cyp154c5, camA, camB, and optionally alkL (one plasmid strategy).

Microorganisms were cultivated in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG. (A) Growth of recombinant strains compared to the wild type (WT). Average values and standard deviations of biological duplicates are presented. (B) SDS-PAGE analysis of heterologous protein levels achieved with the respective strains after different times of induction. Expected proteins are marked with arrows (CYP154C5, 45 kDa; PDR, 45 kDa; AlkL, 23 kDa; Pd, 11 kDa).

(JPG)

pone.0309965.s009.jpg (811KB, jpg)
S7 Fig. Comparison of initial specific progesterone hydroxylation activities of E. coli BL21-Gold(DE3) cells harboring pETM11 equipped with ksa14m with or without alkL.

Resting cells were obtained and used for progesterone hydroxylation assays as described in the Materials and Methods section. As the expected products 2β- and 16β-hydroxyprogesterone (Kille et al., 2011) were not available for calibration curve generation, steroid concentrations were quantified based on standard curves for the similar compound 16α-hydroxyprogesterone and used for the calculation of initial product formation rates (5 min) of strains with or without the hydrophobic outer membrane pore AlkL (biological duplicates).

(TIF)

pone.0309965.s010.tif (128.6KB, tif)
S8 Fig. Growth of E. coli BL21-Gold(DE3) cells carrying plasmids equipped with cyp154c5, camA, camB, and alkL (two plasmid strategy).

All strains contained pACYC-camAB and a second plasmid carrying cyp154c5 or cyp106a2 together with or without alkL on pCOM10_tac (A) or pETM11 (B). Recombinant bacteria were cultivated in M9 medium supplemented with 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG. Data points represent average values and standard deviations of two biological replicates.

(JPG)

pone.0309965.s011.jpg (574.5KB, jpg)
S9 Fig. SDS-PAGE analyses of induced E. coli BL21-Gold(DE3) cells carrying genes encoding CYP154C5 or CYP106A2 (45 kDa), PDR (45 kDa), Pd (11 kDa), and optionally AlkL (23 kDa) separately on two vectors (two plasmid strategy).

Bacteria were grown in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG. Expected proteins are marked with arrows in the respective gel pictures.

(JPG)

pone.0309965.s012.jpg (2.3MB, jpg)
S1 Raw images. Collection of all original SDS gel images contained in the manuscript’s main and supplementary figures.

(PDF)

pone.0309965.s013.pdf (1.3MB, pdf)
S1 Raw data. Minimal data set.

(XLSX)

pone.0309965.s014.xlsx (87.3KB, xlsx)

Acknowledgments

The authors acknowledge the use of the facilities of the Centre for Biocatalysis (MiKat) at the Helmholtz Centre for Environmental Research, which is supported by the European Regional Development Funds (EFRE, Europe funds Saxony) and the Helmholtz Association.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

The study was financially supported by Bayer AG (no grant number). Website: https://www.bayer.com BB aquired the funding and CB was paid from the funding. Bayer AG released the submitted paper for publication. The funders participated in project design, but had no role in study design, data collection and analysis, or preparation of the manuscript.

References

  • 1.Bureik M, Bernhardt R. Steroid hydroxylation: microbial steroid biotransformations using cytochrome P450 enzymes. In: Schmid RD, Urlacher VB, editors. Modern Biooxidation Enzymes, Reactions and Applications. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA; 2007. p. 155–176. [Google Scholar]
  • 2.Donova MV. Steroid bioconversions. Methods Mol Biol. 2017;1645:1–13. doi: 10.1007/978-1-4939-7183-1_1 [DOI] [PubMed] [Google Scholar]
  • 3.Szaleniec M, Wojtkiewicz AM, Bernhardt R, Borowski T, Donova M. Bacterial steroid hydroxylases: enzyme classes, their functions and comparison of their catalytic mechanisms. Appl Microbiol Biotechnol. 2018;102(19):8153–8171. doi: 10.1007/s00253-018-9239-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Julsing MK, Cornelissen S, Bühler B, Schmid A. Heme-iron oxygenases: powerful industrial biocatalysts? Curr Opin Chem Biol. 2008;12(2):177–186. doi: 10.1016/j.cbpa.2008.01.029 [DOI] [PubMed] [Google Scholar]
  • 5.Bernhardt R, Urlacher VB. Cytochromes P450 as promising catalysts for biotechnological application: chances and limitations. Appl Microbiol Biotechnol. 2014;98(14):6185–6203. doi: 10.1007/s00253-014-5767-7 [DOI] [PubMed] [Google Scholar]
  • 6.Lundemo MT, Woodley JM. Guidelines for development and implementation of biocatalytic P450 processes. Appl Microbiol Biotechnol. 2015;99(6):2465–2483. doi: 10.1007/s00253-015-6403-x [DOI] [PubMed] [Google Scholar]
  • 7.Bernhardt R. Cytochromes P450 as versatile biocatalysts. J Biotechnol. 2006;124(1):128–145. doi: 10.1016/j.jbiotec.2006.01.026 [DOI] [PubMed] [Google Scholar]
  • 8.Ortiz de Montellano PR. Cytochrome P450: structure, mechanism, and biochemistry. 3 ed. New York: Springer Verlag; 2005. [Google Scholar]
  • 9.Urlacher VB, Eiben S. Cytochrome P450 monooxygenases: perspectives for synthetic application. Trends Biotechnol. 2006;24(7):324–330. doi: 10.1016/j.tibtech.2006.05.002 [DOI] [PubMed] [Google Scholar]
  • 10.Murdock D, Ensley BD, Serdar C, Thalen M. Construction of metabolic operons catalyzing the de novo biosynthesis of indigo in Escherichia coli. Biotechnology (N Y). 1993;11(3):381–386. doi: 10.1038/nbt0393-381 [DOI] [PubMed] [Google Scholar]
  • 11.Staijen IE, van Beilen JB, Witholt B. Expression, stability and performance of the three-component alkane mono-oxygenase of Pseudomonas oleovorans in Escherichia coli. Eur J Biochem. 2000;267(7):1957–1965. doi: 10.1046/j.1432-1327.2000.01196.x [DOI] [PubMed] [Google Scholar]
  • 12.Duetz WA, van Beilen JB, Witholt B. Using proteins in their natural environment: potential and limitations of microbial whole-cell hydroxylations in applied biocatalysis. Curr Opin Biotechnol. 2001;12(4):419–425. doi: 10.1016/s0958-1669(00)00237-8 [DOI] [PubMed] [Google Scholar]
  • 13.Guengerich FP. Rate-limiting steps in cytochrome P450 catalysis. Biol Chem. 2002;383(10):1553–1564. doi: 10.1515/BC.2002.175 [DOI] [PubMed] [Google Scholar]
  • 14.Narhi LO, Fulco AJ. Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in Bacillus megaterium. J Biol Chem. 1986;261(16):7160–7169. doi: 10.1016/S0021-9258(17)38369-2 [DOI] [PubMed] [Google Scholar]
  • 15.Narhi LO, Fulco AJ. Identification and characterization of two functional domains in cytochrome P-450BM-3, a catalytically self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium. J Biol Chem. 1987;262(14):6683–6690. doi: 10.1016/S0021-9258(18)48296-8 [DOI] [PubMed] [Google Scholar]
  • 16.Kille S, Zilly FE, Acevedo JP, Reetz MT. Regio- and stereoselectivity of P450-catalysed hydroxylation of steroids controlled by laboratory evolution. Nat Chem. 2011;3(9):738–743. doi: 10.1038/nchem.1113 [DOI] [PubMed] [Google Scholar]
  • 17.Bertelmann C, Mock M, Koch R, Schmid A, Bühler B. Hydrophobic outer membrane pores boost testosterone hydroxylation by cytochrome P450 monooxygenase BM3 containing cells. Front Catal. 2022;2:887458. doi: 10.3389/fctls.2022.887458 [DOI] [Google Scholar]
  • 18.Schrewe M, Julsing MK, Bühler B, Schmid A. Whole-cell biocatalysis for selective and productive C-O functional group introduction and modification. Chem Soc Rev. 2013;42(15):6346–6377. doi: 10.1039/c3cs60011d [DOI] [PubMed] [Google Scholar]
  • 19.Woodley JM. Microbial biocatalytic processes and their development. Adv Appl Microbiol. 2006;60:1–15. doi: 10.1016/S0065-2164(06)60001-4 [DOI] [PubMed] [Google Scholar]
  • 20.Bracco P, Janssen DB, Schallmey A. Selective steroid oxyfunctionalisation by CYP154C5, a bacterial cytochrome P450. Microb Cell Fact. 2013;12:95. doi: 10.1186/1475-2859-12-95 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zehentgruber D, Hannemann F, Bleif S, Bernhardt R, Lütz S. Towards preparative scale steroid hydroxylation with cytochrome P450 monooxygenase CYP106A2. ChemBioChem. 2010;11(5):713–721. doi: 10.1002/cbic.200900706 [DOI] [PubMed] [Google Scholar]
  • 22.Bertelmann C, Mock M, Schmid A, Bühler B. Efficiency aspects of regioselective testosterone hydroxylation with highly active CYP450-based whole-cell biocatalysts. Microb Biotechnol. 2024;17(1):e14378. doi: 10.1111/1751-7915.14378 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Whitehouse CJC, Yang W, Yorke JA, Rowlatt BC, Strong AJF, Blanford CF, et al. Structural basis for the properties of two single-site proline mutants of CYP102A1 (P450BM3). Chembiochem. 2010;11(18):2549–2556. doi: 10.1002/cbic.201000421 [DOI] [PubMed] [Google Scholar]
  • 24.Cabiscol E, Tamarit J, Ros J. Oxidative stress in bacteria and protein damage by reactive oxygen species. Int Microbiol. 2000;3(1):3–8. [PubMed] [Google Scholar]
  • 25.Apel K, Hirt H. Reactive oxygen species: metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol. 2004;55:373–399. doi: 10.1146/annurev.arplant.55.031903.141701 [DOI] [PubMed] [Google Scholar]
  • 26.Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Biol. 2011;7(8):504–511. doi: 10.1038/nchembio.607 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kadisch M, Willrodt C, Hillen M, Bühler B, Schmid A. Maximizing the stability of metabolic engineering-derived whole-cell biocatalysts. Biotechnol J. 2017;12(8):1600170. doi: 10.1002/biot.201600170 [DOI] [PubMed] [Google Scholar]
  • 28.Bretschneider L, Heuschkel I, Wegner M, Lindmeyer M, Bühler K, Karande R, et al. Conversion of cyclohexane to 6-hydroxyhexanoic acid using recombinant Pseudomonas taiwanensis in a stirred-tank bioreactor. Front Catal. 2021;1:683248. doi: 10.3389/fctls.2021.683248 [DOI] [Google Scholar]
  • 29.Bühler B, Park J-B, Blank LM, Schmid A. NADH availability limits asymmetric biocatalytic epoxidation in a growing recombinant Escherichia coli strain. Appl Environ Microbiol. 2008;74(5):1436–1446. doi: 10.1128/AEM.02234-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Julsing MK, Kuhn D, Schmid A, Bühler B. Resting cells of recombinant E. coli show high epoxidation yields on energy source and high sensitivity to product inhibition. Biotechnol Bioeng. 2012;109(5):1109–1119. doi: 10.1002/bit.24404 [DOI] [PubMed] [Google Scholar]
  • 31.Harder W, Dijkhuizen L. Physiological responses to nutrient limitation. Annu Rev Microbiol. 1983;37:1–23. doi: 10.1146/annurev.mi.37.100183.000245 [DOI] [PubMed] [Google Scholar]
  • 32.Zhang Y, Song L, Gao Q, Yu SM, Li L, Gao NF. The two-step biotransformation of monosodium glutamate to GABA by Lactobacillus brevis growing and resting cells. Appl Microbiol Biotechnol. 2012;94(6):1619–1627. doi: 10.1007/s00253-012-3868-8 [DOI] [PubMed] [Google Scholar]
  • 33.Willrodt C, Hoschek A, Bühler B, Schmid A, Julsing MK. Decoupling production from growth by magnesium sulfate limitation boosts de novo limonene production. Biotechnol Bioeng. 2016;113(6):1305–1314. doi: 10.1002/bit.25883 [DOI] [PubMed] [Google Scholar]
  • 34.Kuhn D, Kholiq MA, Heinzle E, Bühler B, Schmid A. Intensification and economic and ecological assessment of a biocatalytic oxyfunctionalization process. Green Chem. 2010;12(5):815–827. doi: 10.1039/b921896c [DOI] [Google Scholar]
  • 35.Panke S, Meyer A, Huber CM, Witholt B, Wubbolts MG. An alkane-responsive expression system for the production of fine chemicals. Appl Environ Microbiol. 1999;65(6):2324–2332. doi: 10.1128/AEM.65.6.2324-2332.1999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Wang J, Qin D, Zhang B, Li Q, Li S, Zhou X, et al. Fine-tuning of ecaA and pepc gene expression increases succinic acid production in Escherichia coli. Appl Microbiol Biotechnol. 2015;99(20):8575–8586. doi: 10.1007/s00253-015-6734-7 [DOI] [PubMed] [Google Scholar]
  • 37.Fasan R, Chen MM, Crook NC, Arnold FH. Engineered alkane-hydroxylating cytochrome P450(BM3) exhibiting nativelike catalytic properties. Angew Chem Int Ed Engl. 2007;46(44):8414–8418. doi: 10.1002/anie.200702616 [DOI] [PubMed] [Google Scholar]
  • 38.Fasan R. Tuning P450 enzymes as oxidation catalysts. ACS Catal. 2012;2(4):647–666. doi: 10.1021/cs300001x [DOI] [Google Scholar]
  • 39.Loida PJ, Sligar SG. Engineering cytochrome P-450cam to increase the stereospecificity and coupling of aliphatic hydroxylation. Protein Eng. 1993;6(2):207–212. doi: 10.1093/protein/6.2.207 [DOI] [PubMed] [Google Scholar]
  • 40.Sambrook J, Russell DW. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. [Google Scholar]
  • 41.Choi K-H, Schweizer HP. mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa. Nat Protoc. 2006;1(1):153–161. doi: 10.1038/nprot.2006.24 [DOI] [PubMed] [Google Scholar]
  • 42.Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol. 1983;166(4):557–580. doi: 10.1016/s0022-2836(83)80284-8 [DOI] [PubMed] [Google Scholar]
  • 43.Köhler KA, Rückert C, Schatschneider S, Vorhölter F-J, Szczepanowski R, Blank LM, et al. Complete genome sequence of Pseudomonas sp. strain VLB120 a solvent tolerant, styrene degrading bacterium, isolated from forest soil. J Biotechnol. 2013;168(4):729–730. doi: 10.1016/j.jbiotec.2013.10.016 [DOI] [PubMed] [Google Scholar]
  • 44.Smits THM, Seeger MA, Witholt B, van Beilen JB. New alkane-responsive expression vectors for Escherichia coli and Pseudomonas. Plasmid. 2001;46(1):16–24. doi: 10.1006/plas.2001.1522 [DOI] [PubMed] [Google Scholar]
  • 45.Lindmeyer M, Meyer D, Kuhn D, Bühler B, Schmid A. Making variability less variable: matching expression system and host for oxygenase-based biotransformations. J Ind Microbiol Biotechnol. 2015;42(6):851–866. doi: 10.1007/s10295-015-1615-8 [DOI] [PubMed] [Google Scholar]
  • 46.Lindmeyer M, Jahn M, Vorpahl C, Müller S, Schmid A, Bühler B. Variability in subpopulation formation propagates into biocatalytic variability of engineered Pseudomonas putida strains. Frontiers in Microbiology. 2015;6:1042. doi: 10.3389/fmicb.2015.01042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA 3rd, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009;6(5):343–345. doi: 10.1038/nmeth.1318 [DOI] [PubMed] [Google Scholar]
  • 48.Riesenberg D, Schulz V, Knorre WA, Pohl H-D, Korz D, Sanders EA, et al. High cell density cultivation of Escherichia coli at controlled specific growth rate. J Biotechnol. 1991;20(1):17–27. doi: 10.1016/0168-1656(91)90032-q [DOI] [PubMed] [Google Scholar]
  • 49.Blank LM, Ebert BE, Bühler B, Schmid A. Metabolic capacity estimation of Escherichia coli as a platform for redox biocatalysis: constraint-based modeling and experimental verification. Biotechnol Bioeng. 2008;100(6):1050–1065. doi: 10.1002/bit.21837 [DOI] [PubMed] [Google Scholar]
  • 50.Halan B, Schmid A, Bühler K. Maximizing the productivity of catalytic biofilms on solid supports in membrane aerated reactors. Biotechnol Bioeng. 2010;106(4):516–527. doi: 10.1002/bit.22732 [DOI] [PubMed] [Google Scholar]
  • 51.Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680–685. doi: 10.1038/227680a0 [DOI] [PubMed] [Google Scholar]
  • 52.Chubukov V, Sauer U. Environmental dependence of stationary-phase metabolism in Bacillus subtilis and Escherichia coli. Appl Environ Microbiol. 2014;80(9):2901–2909. doi: 10.1128/AEM.00061-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.McIver AM, Garikipati SV, Bankole KS, Gyamerah M, Peeples TL. Microbial oxidation of naphthalene to cis-1,2-naphthalene dihydrodiol using naphthalene dioxygenase in biphasic media. Biotechnol Prog. 2008;24(3):593–598. doi: 10.1021/bp070416h [DOI] [PubMed] [Google Scholar]
  • 54.Walton AZ, Stewart JD. An efficient enzymatic Baeyer-Villiger oxidation by engineered Escherichia coli cells under non-growing conditions. Biotechnol Prog. 2002;18(2):262–268. doi: 10.1021/bp010177c [DOI] [PubMed] [Google Scholar]
  • 55.Barghini P, Di Gioia D, Fava F, Ruzzi M. Vanillin production using metabolically engineered Escherichia coli under non-growing conditions. Microb Cell Fact. 2007;6:13. doi: 10.1186/1475-2859-6-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Brauer MJ, Yuan J, Bennett BD, Lu W, Kimball E, Botstein D, et al. Conservation of the metabolomic response to starvation across two divergent microbes. Proc Natl Acad Sci U S A. 2006;103(51):19302–19307. doi: 10.1073/pnas.0609508103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Mandelstam J. Turnover of protein in growing and non-growing populations of Escherichia coli. Biochem J. 1958;69(1):110–119. doi: 10.1042/bj0690110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Gottesman S. Proteolysis in bacterial regulatory circuits. Annu Rev Cell Dev Biol. 2003;19:565–587. doi: 10.1146/annurev.cellbio.19.110701.153228 [DOI] [PubMed] [Google Scholar]
  • 59.Walton AZ, Stewart JD. Understanding and improving NADPH-dependent reactions by nongrowing Escherichia coli cells. Biotechnol Prog. 2004;20(2):403–411. doi: 10.1021/bp030044m [DOI] [PubMed] [Google Scholar]
  • 60.Kiss FM, Lundemo MT, Zapp J, Woodley JM, Bernhardt R. Process development for the production of 15β-hydroxycyproterone acetate using Bacillus megaterium expressing CYP106A2 as whole-cell biocatalyst. Microb Cell Fact. 2015;14:28. doi: 10.1186/s12934-015-0210-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Lundemo MT, Notonier S, Striedner G, Hauer B, Woodley JM. Process limitations of a whole-cell P450 catalyzed reaction using a CYP153A-CPR fusion construct expressed in Escherichia coli. Appl Microbiol Biotechnol. 2016;100(3):1197–1208. doi: 10.1007/s00253-015-6999-x [DOI] [PubMed] [Google Scholar]
  • 62.Ishihama A. Adaptation of gene expression in stationary phase bacteria. Curr Opin Genet Dev. 1997;7(5):582–588. doi: 10.1016/s0959-437x(97)80003-2 [DOI] [PubMed] [Google Scholar]
  • 63.Orth JD, Conrad TM, Na J, Lerman JA, Nam H, Feist AM, et al. A comprehensive genome-scale reconstruction of Escherichia coli metabolism. Mol Syst Biol. 2011;7:535. doi: 10.1038/msb.2011.65 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Willrodt C, Karande R, Schmid A, Julsing MK. Guiding efficient microbial synthesis of non-natural chemicals by physicochemical properties of reactants. Curr Opin Biotechnol. 2015;35:52–62. doi: 10.1016/j.copbio.2015.03.010 [DOI] [PubMed] [Google Scholar]
  • 65.Kuhn D, Bühler B, Schmid A. Production host selection for asymmetric styrene epoxidation: Escherichia coli vs. solvent-tolerant Pseudomonas. J Ind Microbiol Biotechnol. 2012;39(8):1125–1133. doi: 10.1007/s10295-012-1126-9 [DOI] [PubMed] [Google Scholar]
  • 66.Kuhn D, Julsing MK, Heinzle E, Bühler B. Systematic optimization of a biocatalytic two-liquid phase oxyfunctionalization process guided by ecological and economic assessment. Green Chem. 2012;14(3):645–653. doi: 10.1039/c2gc15985f [DOI] [Google Scholar]
  • 67.Volmer J, Lindmeyer M, Seipp J, Schmid A, Bühler B. Constitutively solvent-tolerant Pseudomonas taiwanensis VLB120 ΔC ΔttgV supports particularly high-styrene epoxidation activities when grown under glucose excess conditions. Biotechnol Bioeng. 2019;116(5):1089–1101. doi: 10.1002/bit.26924 [DOI] [PubMed] [Google Scholar]
  • 68.Karuzina II, Archakov AI. Hydrogen peroxide-mediated inactivation of microsomal cytochrome P450 during monooxygenase reactions. Free Radic Biol Med. 1994;17(6):557–567. doi: 10.1016/0891-5849(94)90095-7 [DOI] [PubMed] [Google Scholar]
  • 69.Karuzina II, Archakov AI. The oxidative inactivation of cytochrome P450 in monooxygenase reactions. Free Radic Biol Med. 1994;16(1):73–97. doi: 10.1016/0891-5849(94)90245-3 [DOI] [PubMed] [Google Scholar]
  • 70.Bernal V, Castaño-Cerezo S, Canovas M. Acetate metabolism regulation in Escherichia coli: carbon overflow, pathogenicity, and beyond. Appl Microbiol Biotechnol. 2016;100(21):8985–9001. doi: 10.1007/s00253-016-7832-x [DOI] [PubMed] [Google Scholar]
  • 71.Millard P, Enjalbert B, Uttenweiler-Joseph S, Portais J-C, Létisse F. Control and regulation of acetate overflow in Escherichia coli. Elife. 2021;10:e63661. doi: 10.7554/eLife.63661 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Schäfer L, Karande R, Bühler B. Maximizing biocatalytic cyclohexane hydroxylation by modulating cytochrome P450 monooxygenase expression in P. taiwanensis VLB120. Front Bioeng Biotechnol. 2020;8:140. doi: 10.3389/fbioe.2020.00140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.van Beilen JB, Duetz WA, Schmid A, Witholt B. Practical issues in the application of oxygenases. Trends Biotechnol. 2003;21(4):170–177. doi: 10.1016/S0167-7799(03)00032-5 [DOI] [PubMed] [Google Scholar]
  • 74.Bühler B, Schmid A. Process implementation aspects for biocatalytic hydrocarbon oxyfunctionalization. J Biotechnol. 2004;113(1–3):183–210. doi: 10.1016/j.jbiotec.2004.03.027 [DOI] [PubMed] [Google Scholar]
  • 75.Lee K. Benzene-induced uncoupling of naphthalene dioxygenase activity and enzyme inactivation by production of hydrogen peroxide. J Bacteriol. 1999;181(9):2719–2725. doi: 10.1128/JB.181.9.2719-2725.1999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Tegel H, Ottosson J, Hober S. Enhancing the protein production levels in Escherichia coli with a strong promoter. FEBS J. 2011;278(5):729–739. doi: 10.1111/j.1742-4658.2010.07991.x [DOI] [PubMed] [Google Scholar]
  • 77.Terpe K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol. 2006;72(2):211–222. doi: 10.1007/s00253-006-0465-8 [DOI] [PubMed] [Google Scholar]
  • 78.Makart S, Heinemann M, Panke S. Characterization of the AlkS/PalkB-expression system as an efficient tool for the production of recombinant proteins in Escherichia coli fed-batch fermentations. Biotechnol Bioeng. 2007;96(2):326–336. doi: 10.1002/bit.21117 [DOI] [PubMed] [Google Scholar]
  • 79.Panke S, Wubbolts MG, Schmid A, Witholt B. Production of enantiopure styrene oxide by recombinant Escherichia coli synthesizing a two-component styrene monooxygenase. Biotechnol Bioeng. 2000;69(1):91–100. doi: [DOI] [PubMed] [Google Scholar]
  • 80.Silva F, Queiroz JA, Domingues FC. Evaluating metabolic stress and plasmid stability in plasmid DNA production by Escherichia coli. Biotechnol Adv. 2012;30(3):691–708. doi: 10.1016/j.biotechadv.2011.12.005 [DOI] [PubMed] [Google Scholar]
  • 81.Grant C, Deszcz D, Wei Y-C, Martínez-Torres RJ, Morris P, Folliard T, et al. Identification and use of an alkane transporter plug-in for applications in biocatalysis and whole-cell biosensing of alkanes. Sci Rep. 2014;4:5844. doi: 10.1038/srep05844 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Julsing MK, Schrewe M, Cornelissen S, Hermann I, Schmid A, Bühler B. Outer membrane protein AlkL boosts biocatalytic oxyfunctionalization of hydrophobic substrates in Escherichia coli. Appl Environ Microbiol. 2012;78(16):5724–5733. doi: 10.1128/AEM.00949-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Schrewe M, Julsing MK, Lange K, Czarnotta E, Schmid A, Bühler B. Reaction and catalyst engineering to exploit kinetically controlled whole-cell multistep biocatalysis for terminal FAME oxyfunctionalization. Biotechnol Bioeng. 2014;111(9):1820–1830. doi: 10.1002/bit.25248 [DOI] [PubMed] [Google Scholar]
  • 84.Lewis JC, Mantovani SM, Fu Y, Snow CD, Komor RS, Wong C-H, et al. Combinatorial alanine substitution enables rapid optimization of cytochrome P450BM3 for selective hydroxylation of large substrates. Chembiochem. 2010;11(18):2502–2505. doi: 10.1002/cbic.201000565 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Miles CS, Ost TW, Noble MA, Munro AW, Chapman SK. Protein engineering of cytochromes P-450. Biochim Biophys Acta. 2000;1543(2):383–407. doi: 10.1016/s0167-4838(00)00236-3 [DOI] [PubMed] [Google Scholar]
  • 86.Carmichael AB, Wong LL. Protein engineering of Bacillus megaterium CYP102. The oxidation of polycyclic aromatic hydrocarbons. Eur J Biochem. 2001;268(10):3117–3125. doi: 10.1046/j.1432-1327.2001.02212.x [DOI] [PubMed] [Google Scholar]
  • 87.Sowden RJ, Yasmin S, Rees NH, Bell SG, Wong LL. Biotransformation of the sesquiterpene (+)-valencene by cytochrome P450cam and P450BM-3. Org Biomol Chem. 2005;3(1):57–64. doi: 10.1039/b413068e [DOI] [PubMed] [Google Scholar]
  • 88.Noble MA, Miles CS, Chapman SK, Lysek DA, MacKay AC, Reid GA, et al. Roles of key active-site residues in flavocytochrome P450 BM3. Biochem J. 1999;339:371–379. doi: 10.1042/bj3390371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Cryle MJ, Espinoza RD, Smith SJ, Matovic NJ, De Voss JJ. Are branched chain fatty acids the natural substrates for P450BM3? Chem Commun. 2006;(22):2353–2355. doi: 10.1039/b601202g [DOI] [PubMed] [Google Scholar]
  • 90.Munro AW, Leys DG, McLean KJ, Marshall KR, Ost TW, Daff S, et al. P450 BM3: the very model of a modern flavocytochrome. Trends Biochem Sci. 2002;27(5):250–257. doi: 10.1016/s0968-0004(02)02086-8 [DOI] [PubMed] [Google Scholar]
  • 91.Meyer A, Schmid A, Held M, Westphal AH, Röthlisberger M, Kohler H-PE, et al. Changing the substrate reactivity of 2-hydroxybiphenyl 3-monooxygenase from Pseudomonas azelaica HBP1 by directed evolution. J Biol Chem. 2002;277(7):5575–5582. doi: 10.1074/jbc.M110018200 [DOI] [PubMed] [Google Scholar]
  • 92.Jones JP, O’Hare EJ, Wong L-L. Oxidation of polychlorinated benzenes by genetically engineered CYP101 (cytochrome P450cam). Eur J Biochem. 2001;268(5):1460–1467. doi: 10.1046/j.1432-1327.2001.02018.x [DOI] [PubMed] [Google Scholar]
  • 93.Fasan R, Meharenna YT, Snow CD, Poulos TL, Arnold FH. Evolutionary history of a specialized P450 propane monooxygenase. J Mol Biol. 2008;383(5):1069–1080. doi: 10.1016/j.jmb.2008.06.060 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Huang W-C, Westlake ACG, Maréchal J-D, Joyce MG, Moody PCE, Roberts GCK. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency. J Mol Biol. 2007;373(3):633–651. doi: 10.1016/j.jmb.2007.08.015 [DOI] [PubMed] [Google Scholar]
  • 95.Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589. doi: 10.1038/s41586-021-03819-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Volmer J, Neumann C, Bühler B, Schmid A. Engineering of Pseudomonas taiwanensis VLB120 for constitutive solvent tolerance and increased specific styrene epoxidation activity. Appl Environ Microbiol. 2014;80(20):6539–6548. doi: 10.1128/AEM.01940-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Volmer J, Schmid A, Bühler B. The application of constitutively solvent-tolerant P. taiwanensis VLB120ΔCΔttgV for stereospecific epoxidation of toxic styrene alleviates carrier solvent use. Biotechnol J. 2017;12(7):1600558. doi: 10.1002/biot.201600558 [DOI] [PubMed] [Google Scholar]
  • 98.Willrodt C, Gröning JAD, Nerke P, Koch R, Scholtissek A, Heine T, et al. Highly efficient access to (S)-sulfoxides utilizing a promiscous flavoprotein monooxygenase in a whole-cell biocatalyst format. ChemCatChem. 2020;12:4664–4671. doi: 10.1002/cctc.201901894 [DOI] [Google Scholar]
  • 99.Wang Y, Rawlings M, Gibson DT, Labbé D, Bergeron H, Brousseau R, et al. Identification of a membrane protein and a truncated LysR-type regulator associated with the toluene degradation pathway in Pseudomonas putida F1. Mol Gen Genet. 1995;246(5):570–579. doi: 10.1007/BF00298963 [DOI] [PubMed] [Google Scholar]
  • 100.Ruff AJ, Arlt M, van Ohlen M, Kardashliev T, Konarzycka-Bessler M, Bocola M, et al. An engineered outer membrane pore enables an efficient oxygenation of aromatics and terpenes. J Mol Catal B Enzym. 2016;134:285–294. doi: 10.1016/j.molcatb.2016.11.007 [DOI] [Google Scholar]
  • 101.Lee MJ, Kim H-J, Lee J-Y, Kwon AS, Jun SY, Kang SH, et al. Effect of gene amplifications in porphyrin pathway on heme biosynthesis in a recombinant Escherichia coli. J Microbiol Biotechnol. 2013;23(5):668–673. doi: 10.4014/jmb.1302.02022 [DOI] [PubMed] [Google Scholar]
  • 102.Ge J, Wang X, Bai Y, Wang Y, Wang Y, Tu T, et al. Engineering Escherichia coli for efficient assembly of heme proteins. Microb Cell Fact. 2023;22:59. doi: 10.1186/s12934-023-02067-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Hu B, Yu H, Zhou J, Li J, Chen J, Du G, et al. Whole-cell P450 biocatalysis using engineered Escherichia coli with fine-tuned heme biosynthesis. Adv Sci. 2023;10(6):e2205580. doi: 10.1002/advs.202205580 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Schmitz D, Zapp J, Bernhardt R. Steroid conversion with CYP106A2—production of pharmaceutically interesting DHEA metabolites. Microb Cell Fact. 2014;13:81. doi: 10.1186/1475-2859-13-81 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Hannemann F, Virus C, Bernhardt R. Design of an Escherichia coli system for whole cell mediated steroid synthesis and molecular evolution of steroid hydroxylases. J Biotechnol. 2006;124(1):172–181. doi: 10.1016/j.jbiotec.2006.01.009 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Dirk Tischler

16 Jul 2024

PONE-D-24-24922Strategies found not to be suitable for stabilizing high steroid hydroxylation activities of CYP450 BM3-based whole-cell biocatalystsPLOS ONE

Dear Dr. Bühler,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 30 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Dirk Tischler

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

3. Thank you for stating the following financial disclosure: 

   "The study was financially supported by Bayer AG (no grant number).

Website: https://www.bayer.com

B.B. aquired the funding and CB was paid from the funding.

Bayer AG released the submitted paper for publication."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. We note that your Data Availability Statement is currently as follows: All relevant data are within the manuscript and its Supporting Information files.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

5. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Dear Bruno

you will see the comments from the reviewers are supportive and I am looking forward to read the revision. And, as it was hard to appoint reviewers in time and thus we reached holiday saison I understand that it may take time. Still I hope you will improve and send a next version to make a decision.

Sincerely

Dirk

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In their manuscript “Strategies found not to be suitable for stabilizing high steroid hydroxylation activities of CYP450 BM3-based whole-cell biocatalysts”, Bertelmann and Bühler explore various strategies aimed to increase the stability of whole-cell steroid-hydroxylation by Escherichia coli equipped with heterologous cytochrome P450 monooxygenases (CYP450s). Approaches include biotransformation media/buffers with different nutrient compositions, growing cells vs. resting cells, different growth media, different expression systems (prompters, inducers, inducer concentrations), protein engineering, using Pseudomonas as a host, and testing different CYP450 enzymes.

In general, although the authors state that they did not achieve a better system (but see my comment on that below), the work seems to be carefully conducted and is of interest for applied studies.

However, the manuscript should be presented in a more reader-friendly way. The authors assume a lot of knowledge in the abstract and the introduction (see comments).

Also, although the results might indeed be a guideline for further studies, the article is scientifically somewhat unsatisfying, because likely reasons for decreasing activity are discussed, but no data are shown. For example, what about levels of O2 in the biotransforming cell cultures, heme content in CYP450s, or NAD(P)H:NAD(P)+ ratios? If there are values known from literature, I suggest mentioning them, perhaps in the introduction (see my comment Nr. 2).

Finally, I do not understand why the authors did not proceed with, and did not do more experiments on, the plac system (Fig. 4B), and particularly the 0.1 mM IPTG / 0.1 g CDW setup (see my comment Nr. 6). This should be commented on.

In summary, in my opinion, the article could be published without further experiments, but with a thorough editing of the text.

Comments in detail:

1. The abstract is a bit confusing for readers not familiar with this field and the preceding study, respectively. Perhaps the authors may shorten the description of results to make some room for briefly summarizing the former setup that they aimed to optimize.

2. The same holds true for the introduction. It would benefit from introducing CYP450s a bit, such as specifying their cofactors and redox partners, or what is meant by “multi-component nature” (line 48). Also, the previous system should be introduced better, e.g., what is meant by “self-sufficient” (line 51), what is uncoupling (line 62; although this is explained later), what is the KSA14m variant (line 64)… It would also help the readers a lot if you introduced possible optimization steps (or bottlenecks) before delving into the results.

3. Lines 167-168: When the cells are resuspended in potassium phosphate buffer, they are depleted for every nutrient (except K, P; and glucose). Could this influence catalysis and/or stability? For example, what happens with a CYP450 when iron becomes limiting? Why did you not use M9 without nitrogen?

4. Results: Specific activity does not correlate with the enzyme level (e.g., Fig. 1A; Fig. 2). Have you ever purified the enzyme from the cells and checked its cofactor load? Or else, could oxygen be a limiting factor? Since you add glucose, I suppose that the cells have a high respiration rate? The results obtained with low cell concentrations you present in Fig. 4 (and accompanying text) suggest that O2 might not be the limiting factor, but did you ever measure O2 levels in your biotransformation cultures? If you analyzed these things previously, it would be good to mention that. If not, I do not request these analyses for publication of this manuscript, but they might be worth a try in the future.

5. Depending on your response to 4., it might also be worth mentioning that E. coli strains with optimized heme uptake or production have been generated.

6. Also results, Fig. 4: why did you not follow up on the plac system (Fig. 4B), and the 0.1 mM IPTG / 0.1 g CDW setup in particular? It seems to me that it stabilized, although on a somewhat lower than maximally achievable level. Still, did you ever measure activity at later time points? Did you quantify product yields?

7. Do the results shown in Fig. 5B not argue for enzyme destabilization independent from substrate / product concentrations? This could be mentioned much earlier in the manuscript to avoid questions piling up.

8. Lines 495-496: It would be nice for the reader if you would explain what fhuA and todX mean. Also, I assume you want to refer to Fig. 6, not 4.

9. Fig. 6 and results with Pseudomonas, respectively: Obviously, CYP350 levels are not very high in this strain. Did you consider changing expression vectors before dismissing this species completely?

10. Line 545: To evaluate this system, it is important to know the putidaredoxin levels. At least for selected conditions, this should be done, e.g. by higher-percentage gels and/or a Tris/Tricine gel.

11. Conclusions: The manuscript is somewhat overwhelming. I suggest showing a simplified summarizing table.

Minor:

12. Fig. 2A, left panel: the product symbols look like the testosterone symbols after 1 h.

13. Results, Fig. 4 and Fig. 5: Please indicate which resting cell system was applied.

14. Line 440 and line 446: Is it position 87 or 82? Please specify.

15. Table 2 is hard to understand; I’d draw lines between the rows in the lower part.

Reviewer #2: Previously, the same group investigated a whole-cell E. coli-based biocatalyst co-expressing the outer membrane pore AlkL and the P450 BM3 variant KSA14m capable of hydroxylating testosterone primarily to the 15-b-hydroxylated product. During biotransformation, resting cells lose activity due to instability of BM3 monooxygenase. In the present study, the authors tested a number of approaches and varied several factors in an attempt to increase enzyme stability during the process, which could increase the duration of biotransformation and thus lead to higher overall product concentrations. Among other things, they compared resting and growing E. coli cells, varied nutritional conditions during gene expression, different media, promoters, and inducer concentrations. None of these changes resulted in improved cell activity or increased stability of BM3 KSA14m during biotransformation. Interestingly, culture medium and expression strategies influence the initial whole cell activity but not its stability. Furthermore, two additional stabilizing mutations were introduced into the monooxygenase gene, which ultimately did not change the product titer. The use of Pseudomonas instead of E. coli did not improve productivity. Two other steroid hydroxylating P450s, CYP154C5 and CYP106A2, were cloned in E. coli together with the two redox partner genes. While CYP106A2 could not be expressed at all, the biotransformation of testosterone by cells expressing CYP154C5 was found to be no more productive than cells with BM3 KSA14m.

In general, although no improvement could be achieved within this study, the "negative" results can be very helpful for further studies on optimization of whole cell biocatalysts for oxygenation reaction.

I recommend to publish the paper after some revisions:

1. As shown in Figure 2, growing cells continued to express KSA14m even after 24 h of biotransformation (compared to resting cells), but this did not lead to higher biocatalyst productivity. This was explained by a stronger competition of enzyme synthesis and metabolic demands of the reaction with the demands of cellular maintenance and biomass formation. It seems that cell activity (independently if growing or resting) is dependent on the P450 concentration per 1 g cww, as clearly shown in Fig. 2a and Fig. 2b. In the case when the induction was done simultaneously with substrate addion, the specific cell activity first increases with increasing P450 concentration (see the corresponding SDS gel) and then decreases with complete loss after 3.5 h. It would be interesting to measure P450 concentration (using CO difference spectrum). It will not change the situation with the loss of activity after a certain time of biotransformation, but it would allow a more concrete explanation that specific cell activities in growing cells were lower (even at the very beginning of the biotransformation) compared to the resting cells due to lower P450 concentration per cww.

2. It would be helpful for the readers if the genetic construct- AlkL and KSA14m expressed from the same operon – will be described in the introduction section.

3. L. 316-317: “Obviously, KSA14m experienced a similar inactivation in growing as in resting cells,which could not be alleviated by enzyme resynthesis in growing cells”. Compared to resting cells in which the P450 band disappeared after 24 biotransformation, the band corresponding to the P450 remains in growing cells. Could it be that the loss of activity is not only due to protein instability, but due to the loss of heme or FAD or FMN (the prosthetic groups of the reductase domain of P450 BM3)? None of these aspects have been checked in this study, but it is importnat to at least mention them in the discussion.

4. L. 375-377: Please mention the promoters used in this study and their strength compared to each other to make clearer their choice for this study.

5. Was CYP106A2 not active in whole cells or was cloning unsuccessful?

6. Fig.2 In both cases, 700 mkM product concertation was achieved after 2.5 – 4 h starting with 1 mM (=1000 mkM) testosterone. Was the productivity of resting cells used at the same cell density higher?

Reviewer #3: The manuscript presents negative results, however of important biotechnology field. The authors performed many rigorous, well documented and analyzed experiments but were not able to reach desired stability of whole cell oxidation of steroids.

I have only a few recomendations:

1. I am missing a discussion which would discuss more widely the impacts of the findings both to the scientific field as well as to the biotechnology praxis.

2. English is of high level, except of a few wrong articles:

- "the" missing in front of the "most" on several places.

- "a first approach" should be "the" (line 535).

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: Josef Trögl

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Sep 6;19(9):e0309965. doi: 10.1371/journal.pone.0309965.r002

Author response to Decision Letter 0


19 Aug 2024

Response to editor

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

We have revised the manuscript and supporting data to meet the PLOS ONE style requirements according to the templates and the information given by the website.

2. Please note that funding information should not appear in any section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript.

We have removed funding information from the Acknowledgements section of the manuscript (line 653).

3. Thank you for stating the following financial disclosure:

"The study was financially supported by Bayer AG (no grant number).

Website: https://www.bayer.com

B.B. aquired the funding and CB was paid from the funding.

Bayer AG released the submitted paper for publication."

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

The funders participated in project design and approved the submission of the manuscript, but had no role in study design, data collection and analysis, or preparation of the manuscript.

4. We note that your Data Availability Statement is currently as follows: All relevant data are within the manuscript and its Supporting Information files.

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

The minimal data set now is provided in the Supporting Information file “S2_raw_data.xlsx”.

5. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

The first manuscript included two appearances of this phrase:

In line 539, the strain Pseudomonas taiwanensis VLB120_Strep containing the plasmid ptac-ksa14m-alkL did not grow in the LB preculture unlike the other Pseudomonas strains tested. This was a visual observation not based on measured data, but the respective comment was noted in the laboratory journal. Therefore, we have removed the phrase from that sentence.

In line 547, we have added the reference to the corresponding raw image SDS gel.

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

We confirm that the reference list is complete and correct. During revision, following the reviewer recommendations, 16 references have been added to the list (listed in order of appearance):

Bernhardt R. Cytochromes P450 as versatile biocatalysts. J Biotechnol. 2006;124(1):128-145. doi: 10.1016/j.jbiotec.2006.01.026

Ortiz de Montellano PR. Cytochrome P450: structure, mechanism, and biochemistry. 3 ed. New York: Springer Verlag; 2005

Urlacher VB, Eiben S. Cytochrome P450 monooxygenases: perspectives for synthetic application. Trends Biotechnol. 2006;24(7):324-330. doi: 10.1016/j.tibtech.2006.05.002

Murdock D, Ensley BD, Serdar C, Thalen M. Construction of metabolic operons catalyzing the de novo biosynthesis of indigo in Escherichia coli. Biotechnology (N Y). 1993;11(3):381-386. doi: 10.1038/nbt0393-381

Guengerich FP. Rate-limiting steps in cytochrome P450 catalysis. Biol Chem. 2002;383(10):1553-1564. doi: 10.1515/BC.2002.175

Narhi LO, Fulco AJ. Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in Bacillus megaterium. J Biol Chem. 1986;261(16):7160-7169. doi: 10.1016/S0021-9258(17)38369-2

Narhi LO, Fulco AJ. Identification and characterization of two functional domains in cytochrome P-450BM-3, a catalytically self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium. J Biol Chem. 1987;262(14):6683-6690. doi: 10.1016/S0021-9258(18)48296-8

Tegel H, Ottosson J, Hober S. Enhancing the protein production levels in Escherichia coli with a strong promoter. FEBS J. 2011;278(5):729-739. doi: 10.1111/j.1742-4658.2010.07991.x

Terpe K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol. 2006;72(2):211-222. doi: 10.1007/s00253-006-0465-8

Makart S, Heinemann M, Panke S. Characterization of the AlkS/PalkB-expression system as an efficient tool for the production of recombinant proteins in Escherichia coli fed-batch fermentations. Biotechnol Bioeng. 2007;96(2):326-336. doi: 10.1002/bit.21117

Panke S, Wubbolts MG, Schmid A, Witholt B. Production of enantiopure styrene oxide by recombinant Escherichia coli synthesizing a two-component styrene monooxygenase. Biotechnol Bioeng. 2000;69(1):91-100. doi: 10.1002/(sici)1097-0290(20000705)69:1<91::aid-bit11>3.0.co;2-x

Wang Y, Rawlings M, Gibson DT, Labbé D, Bergeron H, Brousseau R, et al. Identification of a membrane protein and a truncated LysR-type regulator associated with the toluene degradation pathway in Pseudomonas putida F1. Mol Gen Genet. 1995;246(5):570-579. doi: 10.1007/BF00298963

Ruff AJ, Arlt M, van Ohlen M, Kardashliev T, Konarzycka-Bessler M, Bocola M, et al. An engineered outer membrane pore enables an efficient oxygenation of aromatics and terpenes. J Mol Catal B Enzym. 2016;134:285-294. doi: 10.1016/j.molcatb.2016.11.007

Lee MJ, Kim H-J, Lee J-Y, Kwon AS, Jun SY, Kang SH, et al. Effect of gene amplifications in porphyrin pathway on heme biosynthesis in a recombinant Escherichia coli. J Microbiol Biotechnol. 2013;23(5):668-673. doi: 10.4014/jmb.1302.02022

Ge J, Wang X, Bai Y, Wang Y, Wang Y, Tu T, et al. Engineering Escherichia coli for efficient assembly of heme proteins. Microb Cell Fact. 2023;22:59. doi: 10.1186/s12934-023-02067-5

Hu B, Yu H, Zhou J, Li J, Chen J, Du G, et al. Whole-cell P450 biocatalysis using engineered Escherichia coli with fine-tuned heme biosynthesis. Adv Sci. 2023;10(6):e2205580. doi: 10.1002/advs.202205580

Response to reviewers

Reviewer #1: In their manuscript “Strategies found not to be suitable for stabilizing high steroid hydroxylation activities of CYP450 BM3-based whole-cell biocatalysts”, Bertelmann and Bühler explore various strategies aimed to increase the stability of whole-cell steroid-hydroxylation by Escherichia coli equipped with heterologous cytochrome P450 monooxygenases (CYP450s). Approaches include biotransformation media/buffers with different nutrient compositions, growing cells vs. resting cells, different growth media, different expression systems (prompters, inducers, inducer concentrations), protein engineering, using Pseudomonas as a host, and testing different CYP450 enzymes.

In general, although the authors state that they did not achieve a better system (but see my comment on that below), the work seems to be carefully conducted and is of interest for applied studies.

However, the manuscript should be presented in a more reader-friendly way. The authors assume a lot of knowledge in the abstract and the introduction (see comments).

Also, although the results might indeed be a guideline for further studies, the article is scientifically somewhat unsatisfying, because likely reasons for decreasing activity are discussed, but no data are shown. For example, what about levels of O2 in the biotransforming cell cultures, heme content in CYP450s, or NAD(P)H:NAD(P)+ ratios? If there are values known from literature, I suggest mentioning them, perhaps in the introduction (see my comment Nr. 2).

Finally, I do not understand why the authors did not proceed with, and did not do more experiments on, the plac system (Fig. 4B), and particularly the 0.1 mM IPTG / 0.1 g CDW setup (see my comment Nr. 6). This should be commented on.

In summary, in my opinion, the article could be published without further experiments, but with a thorough editing of the text.

Comments in detail:

1. The abstract is a bit confusing for readers not familiar with this field and the preceding study, respectively. Perhaps the authors may shorten the description of results to make some room for briefly summarizing the former setup that they aimed to optimize.

We have revised the abstract according to the reviewer’s suggestion (lines 18-33, 40).

2. The same holds true for the introduction. It would benefit from introducing CYP450s a bit, such as specifying their cofactors and redox partners, or what is meant by “multi-component nature” (line 48). Also, the previous system should be introduced better, e.g., what is meant by “self-sufficient” (line 51), what is uncoupling (line 62; although this is explained later), what is the KSA14m variant (line 64)… It would also help the readers a lot if you introduced possible optimization steps (or bottlenecks) before delving into the results.

We agree with this comment and thus have revised the introduction as recommended (lines 44-45, 47-60, 64-71, 74-81, 89, 92). The purpose of this study is now mentioned more clearly in the introduction (lines 84-86) as well as in the beginning of the Results&Discussion section (lines 240-242). Possible optimization steps/bottlenecks are introduced in lines 98-108.

3. Lines 167-168: When the cells are resuspended in potassium phosphate buffer, they are depleted for every nutrient (except K, P; and glucose). Could this influence catalysis and/or stability? For example, what happens with a CYP450 when iron becomes limiting? Why did you not use M9 without nitrogen?

The lack or depletion of nutrients can indeed affect catalysis as well as stability due to their respective demand in the whole-cell biocatalyst’s metabolism. In this study, the standard biotransformation setup with resting (i.e., non-growing but metabolically active) cells included potassium, phosphate, and glucose as sole components, as it also has broadly been reported in literature. The lack of a nitrogen source thereby is used to achieve a growth limitation, which transfers the cells into a resting, but metabolically active state. In this state, competition of metabolic demands of the biocatalytic reaction with cellular maintenance and biomass formation is reduced. This often allows superior specific biotransformation rates of resting cells compared to growing cells (as also observed in this study, Figs. 1 and 2), ultimately resulting in increased product yields on energy source as well as facilitated reusability and downstream processing. However, omitting nitrogen from the biotransformation medium implies a down-regulation of biosynthetic capacities, especially the efficient (re )synthesis of enzymes and energy/redox carriers, which can affect the operational stability during the biotransformation (explained in lines 251-263, 277-283). This is the reason why we tested M9 without magnesium to exclude effects of other nutrients including nitrogen or iron. Similar activities were observed. Just deprivation of magnesium still allows some growth as shown in an earlier study, in which M9 medium without magnesium allowed better performance than M9 medium without nitrogen, whereas the latter did not result in differences compared to Kpi buffer with glucose (Willrodt C, Hoschek A, Bühler B, Schmid A, Julsing MK. Decoupling production from growth by magnesium sulfate limitation boosts de novo limonene production. Biotechnol Bioeng. 2016;113(6):1305-1314. doi: 10.1002/bit.25883). This information was added (lines 263-267).

4. Results: Specific activity does not correlate with the enzyme level (e.g., Fig. 1A; Fig. 2). Have you ever purified the enzyme from the cells and checked its cofactor load? Or else, could oxygen be a limiting factor? Since you add glucose, I suppose that the cells have a high respiration rate? The results obtained with low cell concentrations you present in Fig. 4 (and accompanying text) suggest that O2 might not be the limiting factor, but did you ever measure O2 levels in your biotransformation cultures? If you analyzed these things previously, it would be good to mention that. If not, I do not request these analyses for publication of this manuscript, but they might be worth a try in the future.

We initially aimed to purify the enzyme based on the 6x-His-tag at the N-terminal end of the enzyme for a thorough evaluation of its specific kinetic properties and uncoupling behavior (i.e., uncoupling of NADPH oxidation and substrate hydroxylation). Our attempts however were not successful due to impurity of the final eluates, which may severely influence the respective experimental outcome.

Regarding the measurement of oxygen in the biotransformation cultures: Oxygen levels were not measured for the experiments presented in this manuscript and therefore no data is available in this regard. We agree that oxygen-dependent reactions in whole-cell biocatalysis can be limited by oxygen mass transfer, especially in closed systems. In our study, assays featured a volume ratio of liquid : headspace of 1 : 11, and, for reaction time course analysis, tubes were opened regularly for sampling. Moreover, in our previous study, we investigated oxygen as limiting factor by varying biomass co

Attachment

Submitted filename: Response to Reviewers.docx

pone.0309965.s015.docx (570KB, docx)

Decision Letter 1

Dirk Tischler

22 Aug 2024

Strategies found not to be suitable for stabilizing high steroid hydroxylation activities of CYP450 BM3-based whole-cell biocatalysts

PONE-D-24-24922R1

Dear Dr. Bühler,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Dirk Tischler

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Dear Prof. Bühler

the changes made improved the manuscript as suggested by the three reviewers and hence I accept the revised version.

Sincerely!

Reviewers' comments:

Acceptance letter

Dirk Tischler

27 Aug 2024

PONE-D-24-24922R1

PLOS ONE

Dear Dr. Bühler,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Asst. Prof. Dr. Dirk Tischler

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Primer sequences and PCR templates used for the construction of the plasmids used in this study.

    (PDF)

    pone.0309965.s001.pdf (307.6KB, pdf)
    S2 Table. Components and settings of site-directed mutagenesis PCR to introduce M82A and L188P amino acid exchanges into KSA14m.

    (PDF)

    pone.0309965.s002.pdf (110.8KB, pdf)
    S3 Table. Composition and preparation of minimal media used in this study.

    (PDF)

    pone.0309965.s003.pdf (15.7KB, pdf)
    S1 Fig. Genetic constructs applied for co-expression of the genes encoding the 6xHis-tagged BM3 variant KSA14m and the hydrophobic outer membrane protein AlkL in a bicistronic operon under control of different expression systems.

    Heterologous gene expression was either realized via (A) the T7 promoter (PT7), (B) the alkB promoter (PalkB), (C) the lacUV5 promoter (PlacUV5), or (D) the tac promoter (Ptac) based on either LacIq (A, C, D) or AlkS (B) as regulators. The creation of plasmids pETM11-ksa14m-alkL (A), palk-ksa14m-alkL (B), plac-ksa14m-alkL (C), and ptac-ksa14m-alkL (D) is explained in S1 Table.

    (JPG)

    pone.0309965.s004.jpg (408.1KB, jpg)
    S2 Fig. Courses of product formation during biocatalytic testosterone hydroxylation with resting and growing E. coli BL21-Gold(DE3) cells.

    Microorganisms were cultivated in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG. Biotransformations were conducted as described in the Materials and Methods Section. Average values and standard deviations of two biological replicates are shown.

    (TIF)

    pone.0309965.s005.tif (507.4KB, tif)
    S3 Fig. SDS-PAGE analyses for E. coli BL21-Gold(DE3) strains producing KSA14m (119 kDa, black arrows) and AlkL (23 kDa, grey arrows) under control of different gene expression systems (see S1 Fig) and with different inducer concentrations.

    Microorganisms were cultivated in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced in the early exponential phase. (A) AlkS-PalkB-based regulatory system, induced with different DCPK concentrations. (B) LacI-PlacUV5-based expression system, induced with different IPTG concentrations. (C) LacIq-Ptac-based expression system, induced with different IPTG concentrations. (D) LacI-PT7-based regulatory system, either uninduced or induced with different IPTG concentrations.

    (JPG)

    pone.0309965.s006.jpg (2.6MB, jpg)
    S4 Fig. Growth of E. coli BL21-Gold(DE3) strains carrying pETM11 equipped with alkL and either the original ksa14m gene or variants thereof (ksa14mutations, ksa14m_M82A, ksa14m_L188P).

    Bacterial cells were grown in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG in the early exponential phase. Average values and standard deviations of two biological replicates are given.

    (TIF)

    pone.0309965.s007.tif (190.2KB, tif)
    S5 Fig. Genetic constructs applied for co-expression of genes encoding alternative steroid hydroxylation systems.

    Necessary genes encoded either CYP154C5 or CYP106A2 (cyp), redox partner proteins (camA for putidaredoxin reductase, PDR, and camB for putidaredoxin, Pd), as well as the hydrophobic outer membrane protein AlkL (alkL). I) One plasmid strategy: one vector for the synthesis of 6xHis-tagged CYP154C5, PDR, Pd, and AlkL under control of the LacI-PT7-based expression system. II) Two plasmid strategy: cyp/alkL and camA/camB were expressed from two separate plasmids. Final bacterial strains always contained plasmid A (pACYC-camAB) carrying camA and camB under control of two separate T7 promoters. In addition, the cells harbored either plasmid B1 or B2 carrying the respective cyp genes and alkL under control of PT7 (B1) or Ptac (B2). Plasmid construction is detailed in S1 Table.

    (JPG)

    pone.0309965.s008.jpg (502.6KB, jpg)
    S6 Fig. Performance of E. coli BL21-Gold(DE3) cells carrying pETM11 equipped with cyp154c5, camA, camB, and optionally alkL (one plasmid strategy).

    Microorganisms were cultivated in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG. (A) Growth of recombinant strains compared to the wild type (WT). Average values and standard deviations of biological duplicates are presented. (B) SDS-PAGE analysis of heterologous protein levels achieved with the respective strains after different times of induction. Expected proteins are marked with arrows (CYP154C5, 45 kDa; PDR, 45 kDa; AlkL, 23 kDa; Pd, 11 kDa).

    (JPG)

    pone.0309965.s009.jpg (811KB, jpg)
    S7 Fig. Comparison of initial specific progesterone hydroxylation activities of E. coli BL21-Gold(DE3) cells harboring pETM11 equipped with ksa14m with or without alkL.

    Resting cells were obtained and used for progesterone hydroxylation assays as described in the Materials and Methods section. As the expected products 2β- and 16β-hydroxyprogesterone (Kille et al., 2011) were not available for calibration curve generation, steroid concentrations were quantified based on standard curves for the similar compound 16α-hydroxyprogesterone and used for the calculation of initial product formation rates (5 min) of strains with or without the hydrophobic outer membrane pore AlkL (biological duplicates).

    (TIF)

    pone.0309965.s010.tif (128.6KB, tif)
    S8 Fig. Growth of E. coli BL21-Gold(DE3) cells carrying plasmids equipped with cyp154c5, camA, camB, and alkL (two plasmid strategy).

    All strains contained pACYC-camAB and a second plasmid carrying cyp154c5 or cyp106a2 together with or without alkL on pCOM10_tac (A) or pETM11 (B). Recombinant bacteria were cultivated in M9 medium supplemented with 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG. Data points represent average values and standard deviations of two biological replicates.

    (JPG)

    pone.0309965.s011.jpg (574.5KB, jpg)
    S9 Fig. SDS-PAGE analyses of induced E. coli BL21-Gold(DE3) cells carrying genes encoding CYP154C5 or CYP106A2 (45 kDa), PDR (45 kDa), Pd (11 kDa), and optionally AlkL (23 kDa) separately on two vectors (two plasmid strategy).

    Bacteria were grown in M9 medium containing 0.5% (w/v) glucose and heterologous gene expression was induced with 0.1 mM IPTG. Expected proteins are marked with arrows in the respective gel pictures.

    (JPG)

    pone.0309965.s012.jpg (2.3MB, jpg)
    S1 Raw images. Collection of all original SDS gel images contained in the manuscript’s main and supplementary figures.

    (PDF)

    pone.0309965.s013.pdf (1.3MB, pdf)
    S1 Raw data. Minimal data set.

    (XLSX)

    pone.0309965.s014.xlsx (87.3KB, xlsx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0309965.s015.docx (570KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES